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ABSTRACT 
 
 
 The increased use of direct-to-consumer (DTC) advertising of 
prescription pharmaceuticals has caused everyone from physicians and 
patients to congressmen and professionals to question the ethics of the 
practice.  Although the Federal Drug Administration (FDA) regulates 
advertising content, healthcare professionals often criticize the practice on the 
basis of weakening the doctor-patient relationship and jeopardizing patient 
well-being.  Pharmaceutical companies have found print and broadcast ads in 
DTC campaigns to greatly increase the sales of their products. However, 
because of the impact of DTC on patient lives and health, the ethics of the 
practice need examination. 
 The purpose of this thesis is to determine whether current DTC efforts 
are ethical and to create a model for ethical decision-making within the 
industry. In order to provide an effective model that satisfies ethical 
boundaries as well as corporate financial goals, I create a synthesis employing a 
normative approach with stakeholder theory from business ethics so that the 
large number of groups affected by DTC campaigns can have their needs 
appropriately addressed.  Once an ethical model has been outlined, I analyze 
the visual and linguistic features of DTC advertisements to determine areas for 
 iii
 
 
 
ethical revision. I conclude with strategies for DTC decision-makers that 
satisfy ethical parameters while also enhancing the reputation and, thus, the 
success of pharmaceutical companies that utilize DTC campaigns.  
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CHAPTER 1 
 
INTRODUCTION 
 
 
 In the past fifteen years, the pharmaceutical industry has significantly 
increased the amount of direct-to-consumer (DTC) advertising used to 
promote prescription products to a diverse audience, thus significantly 
increasing product sales. Patients become aware of prescription medications 
through television commercials and magazine advertisements, often leading 
them to self-diagnose or to request a particular prescription from their 
physician.  While the US Food and Drug Administration (FDA) has developed 
a set of regulations for drug advertisements, many physicians worry that 
marketing prescription products to an audience with little medical knowledge 
leads to problematic patient self-diagnosis and possible dangerous effects.  This 
concern may be attributed to the way in which information is supplied in ads 
and the ethical implications of current corporate goals to both provide valid 
product information and to increase company profits.  The FDA mandates that 
ads give a brief summary of the benefits and possible side effects of the product 
in question; however, DTC ads are geared more towards product sales than 
patient education, thus the language used and message conveyed in the ads is 
often biased towards pharmaceutical sales.   
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Advertising executives who create DTC campaigns could be put into an 
ethical dilemma if their personal ethics do not coincide with the moral and 
financial objectives of their company.  By analyzing the practices of both 
individuals and corporate entities that have a stake in DTC advertising, ethical 
roadblocks can be determined though a solution may be more difficult to 
achieve.  The purpose of this thesis is to examine the current ethical problems 
that exist within pharmaceutical advertising both on an individual and 
corporate basis, and to prescribe possible ethical strategies to accomplish 
corporate goals of increased sales as well as keep patients safe.  In order to 
focus this thesis, I will not examine all DTC advertisements, but instead make 
suggestions tailored towards the largest therapeutic area within 
pharmaceutical marketing: statins.  
 Statins are prescription medications approved by the FDA to reduce or 
prevent high cholesterol levels in patients.  First created in 1987, statins 
quickly became the fastest growing therapeutic area in pharmaceutical history.  
In recent years, nations across the globe have spent more money on statins 
than on any other medication, “generat[ing] revenues of more than $25 billion 
a year for their manufacturers” (Moynihan and Cassels 1).  Although statins 
have improved the health of many patients, some physicians are concerned 
that marketing efforts have generated a false sense of need with the patient 
population.  Since statins corner such a large percentage of the prescription 
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market, it is not surprising that DTC advertisements for the drugs can be found 
throughout popular magazines and during high traffic time slots on television.  
This thesis focuses primarily on statins because they are the largest therapeutic 
area in the world, affecting the largest number of both potential and current 
patients. 
 The target audience customers for pharmaceuticals vary greatly across 
national and international boundaries, thus this thesis will only pertain to the 
use of DTC advertisements in the U.S., as this is the only country that 
promotes prescription pharmaceuticals to the general public (“New Zealand”).  
Although most marketing materials are produced through a collaborative 
effort, it is important to analyze the ethical practices of individuals in relation 
to group ethics.  Many of the issues that I will assess in this thesis pertain to all 
professional practices; however, the promotion of healthcare products brings 
ethics to the forefront of professional goals because the end result impacts the 
physical wellbeing of an individual.  Since preventative medications, such as 
statins, are becoming the largest sector of the pharmaceutical industry, it is 
necessary to establish ethical strategies within the corporation for DTC 
promotional efforts that will improve moral decision-making and, in turn, 
help the business.          
 The primary purpose of this thesis is to determine ethical strategies for 
DTC advertisements that will benefit all stakeholders from the corporation to 
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the consumer.  In the remainder of this chapter, I will discuss the scope of 
DTC advertising in order to emphasize the impact this marketing tactic can 
have on the general public.  In Chapter 2, I will provide an overview of the 
FDA regulations for DTC advertisements and will introduce readers to the 
verbal and visual rhetoric behind statin ads in order to provide readers with a 
basic understanding of the legal implications and formal layout of DTC 
advertisements in the referenced market.  Chapter 3 emphasizes the role of 
ethics in business, in marketing, and in the medical field.  Here, I will form the 
foundation of what is considered ethical in different professional settings so 
that the fusion between DTC advertisements and ethics, the purpose of 
Chapter 4, can lend itself to an analysis of ethical and non-ethical practices 
within the promotional efforts of statins.  In Chapter 5, I will present ethical 
strategies for DTC campaigns that will make “good” business sense to decision-
makers in the pharmaceutical industry while also satisfying ethical goals of 
physicians, consumers, the FDA, and all other stakeholders.  The thesis 
concludes with a brief discussion concerning the future of statins and new 
advertising technologies. 
History of DTC Advertising 
 Direct to consumer (DTC) advertising has become one of the most 
effective ways pharmaceutical companies increase the sale of their products.  A 
1992 study of the frequency of particular advertisements during prime time 
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television indicated that no ads were displayed for prescription pharmaceutical 
products; however, in just six years, an average of four prescription ads were 
visible during the same time slot and on the same channels (Byrd-Bredbenner 
and Grasso 63).  The presence of DTC ads has grown within the industry since 
that 1992 study with pharmaceutical companies spending around $2.7 billion 
in 2001 (Rados).  A study conducted between 1999 and 2000 by the Kaiser 
Family Foundation, a national health philanthropy, found that DTC ads 
accounted for 14% of spending by pharmaceutical companies, which 
translated into $4.20 in additional sales that year for each dollar spent (“Impact 
of Direct”).  These are significant figures considering the billions of dollars 
pharmaceutical companies make each year and the significant rise in the cost 
of healthcare coverage over the past decade.  With such an increase in the 
number of ads and in the price of medications, many consumers and 
physicians have begun to debate the safety and educational value of DTC 
advertising. 
 Some physicians ridicule DTC ads claiming that they present biased 
and inaccurate medical information and that patients can obtain a false sense 
of need for a medication because they are not fully educated about the 
product.  These physicians feel that the ads often present misleading 
information and cause patients to self diagnose an otherwise non-existent 
ailment (“Impact of Direct”).  The argument goes along with the notion that 
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the concise form of a DTC advertisement cannot educate a consumer, but 
rather, it can only provide condensed slices of information.  This contention 
raises an important distinction between educating a consumer (i.e., providing 
them with enough information to make informed decisions) and informing 
consumers of product features.  Theorists such as Steven Katz might go further 
to assert that words such as educate and inform all “reflect a view of 
communication as a one-way process-from expert (scientist, industry rep, 
government official) to public” (Katz 5).  In this sense, advertising is not a two-
way system where the audience has the opportunity to ask questions, offer 
opinions, and actively construct knowledge; rather, the audience is educated-
informed-about product features.  Although the conversation between patients 
and physicians that DTC advertising encourages can be viewed as two-way 
communication, the DTC advertisements may be perceived as a one-way 
transmission from the pharmaceutical company to consumers.  Unless 
specifically noted, the use of “educate” and “inform” or “education” and 
“information” will only refer to the message conveyed by DTC advertisements, 
which is the way pharmaceutical companies and businesses in general use the 
terms.  Physicians are not all in agreement over the use of DTC campaigns, 
with some arguing that advertisements can misrepresent the medical 
conditions by selective editing of the number and types of symptoms that are 
presented to the general public (“Impact of Direct”).  Opponents of DTC 
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advertisements further contend that because the ads present such convincing 
arguments, many patients are convinced that they have an illness, sometimes 
causing them to get second and even third opinions when their family doctor 
will not prescribe the marketed medication (“Impact of Direct”).  Not only do 
the ads convince patients that they suffer from the advertised condition, but 
ads also cause some patients to pressure doctors to prescribe the medication 
when they otherwise would not.  According to the FDA’s 2002 survey of 500 
physicians, 28 percent felt at least “somewhat pressured to prescribe the 
specific name brand drug when the patient asked the physician to do so” 
(Woodcock), meaning that over one quarter of the physicians surveyed 
acknowledged that patient questioning plays a role in their prescribing habits, 
thus stressing the impact an ad campaign can have on a person’s health.   
 Proponents of DTC pharmaceutical advertising are not just 
pharmaceutical companies and a few physicians; the FDA also supports the 
educational and health values that the ads provide, but for different reasons.  
Advocates of prescription DTC ads argue that the campaigns encourage patient 
awareness of medical ailments, sometimes helping them discover illnesses at 
an early stage and often bringing an illness to the attention of their physician 
(Rados).  Recent research conducted by Kimberly Emmons of Case Western 
Reserve University, indicates that the rhetorical discourse of DTC ads has 
significantly changed the relationships between patients, physicians, and 
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pharmaceutical companies.  Emmons asserts that the new discourse generated 
by the ads, places the consumer and the pharmaceutical company in the role of 
healthcare decision-makers (Emmons ).  The validity of this assertion is 
further supported by FDA research findings same 2002 FDA survey of 500 
physicians mentioned earlier: “forty percent of physicians believe that patients 
understood well the possible risks and negative effects of an advertised drug 
from the DTC ad alone” (Woodcock).  Based on this survey and other studies, 
the FDA concludes that “accurate” DTC campaigns “can lead to significant 
increases in the detection of under-treated conditions such as high blood 
pressure, diabetes, and depression, with consequent health benefits for 
Americans” (Woodcock).  With proponents of DTC campaigns asserting that 
promotional efforts are an effective form of patient awareness, the FDA serves 
to monitor the way in which a pharmaceutical company presents product 
information to an audience that often does not fully understand the illness that 
needs to be treated. 
Current State of Direct-to-Consumer Advertisements 
Advertisements have been used by corporations for decades to 
encourage consumers to buy products ranging from bubble gum and snack 
food to cough syrup and toothpaste.  Over the years, television and print 
media, especially magazines and newspapers, have become the most 
prominent places advertisers use to promote their products.  Although these 
 8
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media have traditionally been used to market everyday products to consumers, 
the past decade has introduced a new range of products for consumers to 
consider, prescription medications.  In the past, pharmaceutical companies 
marketed their products primarily to physicians and pharmacists in an attempt 
to increase product sales, but now direct-to-consumer advertising is 
commonplace and has hit the market with a surge in pharmaceutical sales 
(Buckley 5).  As mentioned earlier, the introduction of prescription products 
to consumers with little to no medical background raises many questions as to 
the safety and efficacy of such marketing campaigns.   
Within DTC campaigns of prescription medication, consumers are 
often provided with a series of questions that relate to a sampling of 
characteristics associated with medical problems such as high cholesterol, 
depression, overactive bladder, and a variety of other health issues (see Figure 
1.1).  While print ads are often accompanied by a copy of a package insert (PI), 
which provides FDA approved medical information about the product (see 
Figure 1.2); television ads rarely contain such information.  DTC ads often 
encourage consumers to consult their physician to see if they need a 
prescription for the product being marketed, creating questions as to the 
educational value of the ads.  
10 
 
 
 
Figure 1.1. Heart Attack DTC Risk Assessment, Pravachol.  Advertisement.  Prevention.  January 1998. 
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Figure 1.2. PI Information Found on the Reverse Side of the Same Advertisement, Pravachol.  Advertisement.  Prevention.  January 1998.
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The DTC Debate 
 Direct-to-consumer advertising of prescription pharmaceuticals is not a 
new thing.  Although the advertising of pharmaceuticals began as an effort 
directed at physicians, the practice became less successful in the early 1980s as 
the competition among pharmaceutical companies rose and scores of “me-too” 
products were launched into the market (White 232).  When DTC advertising 
of prescription products began in the early 1980s, the FDA had very few 
restrictions on the ads; however, as marketing expanded and the debate over 
the ethics and educational value of the ads increased, the FDA was forced to 
create detailed restrictions on DTC efforts (Jaramillo 267).  Traditionally, the 
Federal Trade Commission (FTC) was the government agency in charge of 
monitoring all advertisements, but pharmaceutical ads posed a new challenge.  
Since the advertisements deal with health related products, the FDA was put 
in charge of all pharmaceutical product labeling and advertising (Jaramillo 
267).  
 The FDA has been presented with a unique challenge because the 
targeted audience of prescription products is much more elaborate than that of 
traditional consumer goods.  While many products in the world market are 
targeted towards specific ages, genders, races, etc., prescription 
pharmaceuticals are often targeted towards a more all-encompassing audience.  
When drug companies first started to market their products after the 
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introduction of penicillin in 1945, physicians were the only targeted 
individuals for promotional campaigns.  Now, companies struggle to meet the 
expectations of a range of stakeholders: physicians, nurses, pharmacists, 
“payers,” and patients (Wadman and Hutt).  The expansion of marketing 
targets introduces a problem for strategists because each group of stakeholders 
typically prefers to hear about specific features and benefits of a product based 
on their cultural needs.  This shift within the past few years makes creating a 
promotional strategy for even a small, localized group a difficult task because 
of the diversity of groups affected.  
The United States has not always been the only country to allow DTC 
pharmaceutical advertisements.  New Zealand, Canada, and parts of Europe 
allowed these marketing campaigns in the past, but the presence of this 
marketing tactic has incurred a flood of criticism from the medical community 
and reduced its presence worldwide.  Healthcare professionals fall on both side 
of the debate, with patient education being the foremost issue.  Few people 
argue that DTC pharmaceutical advertisements have not been successful, 
because corporate profits have surged since the ads hit the market and 
advertising budgets have skyrocketed.  Pharmaceutical companies have always 
spent a great deal to market their products to the healthcare community and 
the budget continues to rise with total DTC spending amounting to $4 billion 
in 2004 alone (White 232).  The controversy surrounding the use of DTC 
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tactics is centered upon whether or not the advertisements educate patients 
about the use and risks of a medication and the illness it can treat.   
Proponents of DTC advertising such as Pharmaceutical Research and 
Manufacturers of America (PhRMA), an organization that represents leading 
pharmaceutical research and biotechnology companies, argue that advertising 
prescription products directly to the consumer is beneficial because it informs 
people about illnesses and remedies that they may not have previously been 
aware (Buckley 4).  The assertion is that advertisements provide consumers 
with a basic understanding of the illness as well as a course of action to 
prevent or treat the ailment.  In this scenario, the general public understands 
the risks and side effects of a product after reading or watching the ad and is, 
in turn, encouraged to seek further information by consulting their personal 
physician.  Not surprisingly, pharmaceutical giants such as Pfizer, the largest 
pharmaceutical company in the world, assert that the ads strengthen doctor-
patient relationships.  Corporations are prepared for the debate, even including 
their “policy” on DTC advertising on the company website such as Pfizer’s 
stance on the ads: 
Pfizer believes that patients benefit from information about 
diseases and medical treatment options because when they learn 
about symptoms and therapies, they can engage in a more 
informed discussion with their healthcare provider.  One way 
that disease and treatment information is made available is 
through advertising. (“Access and Affordability: Advertising and 
Promotion”)   
 14
 
 
It is interesting to note that Pfizer’s statement does not acknowledge 
persuasive tactics presented in DTC efforts, but rather, the transmission of 
information is at the heart of their defense of the advertisements.  The 
statement above asserts that the advertisements encourage the doctor-patient 
relationship by allowing for a more “informed discussion,” but the extent of 
the patient’s knowledge of the drug is not considered.  Proponents of DTC 
campaigns rely on this contention that the ads facilitate two-way 
communication between an “informed” patient and their physician; however, 
it is unclear whether the patients are simply made aware of an illness or if they 
are, in fact, informed of the condition by ads.  Despite this distinction, the 
FDA agrees with proponents of DTC ads and contends that the marketing 
tactic is educational for patients and, thus, is beneficial.   
Opponents of the marketing strategy assert that the advertisements go 
against the idea that prescription products are made available to consumers 
through medical specialists who have a thorough understanding of their 
patient’s medical history and of the affect the drug will (or should) have on the 
patient (Wilkes et. al.).  Some worry that DTC ads encourage patients to self-
diagnose an illness and then put pressure on their physician to prescribe the 
product.  This may be the case with a 1998 study by Prevention magazine 
showing that, “15.1 million U.S. consumers asked their physician for a 
medication they saw advertised, and that physicians honoured those requests 
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eighty percent of the time, which translates into 12.1 million prescriptions 
generated by advertising” (Buckley 6).  These are staggering figures 
considering that DTC spending just one year later, in 1999, totaled $1.824 
billion and that number has more than doubled today (Jaramillo 271). 
The debate over the effectiveness of DTC pharmaceutical 
advertisements continues to be a hot topic both within the healthcare 
community, within Congress, and within the FDA, the organization in charge 
of regulating all promotional activities conducted by pharmaceutical 
companies.  In order to make sure that DTC pharmaceutical advertisements 
were considered beneficial by a majority of physicians and potential 
consumers, the FDA conducted three primary studies over the course of the 
past fifteen years in order to determine whether or not the campaigns are 
effective in patient education.  The results of the two most recent studies were 
published by the FDA in January of 2003 in a report entitled, Assessment of 
Physician Attitudes Toward Direct-to-Consumer Promotion of Prescription 
Products.  The report describes the methodology and results of two national 
surveys conducted by the FDA in 1999 and 2002.  In each study, a random 
sample of roughly 1000 participants who had visited a physician within the 
past three months were selected to complete a sixty-five question survey 
consisting of solely quantitative questions  (Patient and Physician Attitudes 
“Appendix B.2”).  The questions ranged from a “yes or no” format to a Likert 
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scale and covered areas such as why the patient went to the doctor, whether or 
not they visited because of an advertisement, and whether or not they agree 
that prescription advertisements make them want a specific drug.  The same 
format of questioning was followed for physicians, including questions such as 
how many patients they see in a week, whether or not a patient mentioned an 
advertisement during their visit, and if so, did the ad cause any problems 
during the visit (Patient and Physician Attitudes “Appendix B.3”).   
The surveys were conducted by means of recorded interviews and 
researchers maintained certain qualifications for participants.  For example, 
the patient survey indicated that the only qualifications of a participant were 
that they must be at least eighteen years of age and must have visited their 
physician within the past three months.  To qualify as a participant, physicians 
only had to be actively seeing patients within the past three months (Patient 
and Physician Attitudes “Appendix B.2”).  This allowed the patient sampling to 
be broad and not focused on a specific age, race, or educational status. 
The researchers determined that 88% of the patients, who asked their 
doctor about a prescription ad they saw, actually had the illness (Rados).  Of 
the patients surveyed, 90% could remember the benefits of the drug being 
marketed and its side effects and 89% could recall who should not take the 
medication (Rados).  A majority of the physicians surveyed, 53%, admitted 
that DTC campaigns led to better discussions with their patients and 42% felt 
 17
 
 
the patients were more aware of treatments (Rados).  Although a majority of 
physicians agreed that the ads aided in discussion with their patients, only 
10% of the physicians felt that DTC advertisements informed or educated their 
patients (Rados).  Based on these figures, the FDA concluded that DTC 
campaigns effectively educate patients enough to encourage them to seek the 
opinion of a doctor.  Although the results of the studies reveal DTC advertising 
to be educational and beneficial to patients, the debate over DTC ads has also 
prompted more detailed regulations for the ads as will be discussed in the next 
chapter.   
 
 18
 
 
 
 
CHAPTER 2 
TYPES OF DTC ADVERTISEMENTS AND FDA REGULATIONS 
 
 The purpose of this chapter is to identify DTC advertising 
classifications and to outline the rules and regulations set forth by the FDA to 
govern ad content.  Here, I hope to provide the FDA regulations for print and 
broadcast ads and to discuss the procedures the FDA uses to reprimand 
pharmaceutical companies that do not follow protocol.  Since the FDA is in 
charge of monitoring the advertisements created and distributed by 
pharmaceutical companies, officials have created specific regulations for print 
media, television and broadcast commercials, and Internet marketing.  Each 
medium reaches staggering numbers of consumers with print and television 
ads comprising the greatest consumer reach.  Print advertisements for 
pharmaceuticals can be found in virtually every type of magazine from 
Reader’s Digest and Good Housekeeping to Health and Prevention.  Broadcast 
commercials are even more visible.  A 2003 survey indicated that 86% of all 
consumers either saw or heard a television advertisement for a prescription 
drug (Bodenheimer W3-114).  Not to be outdone, the Internet is used to 
market pharmaceutical products to millions of consumers through product 
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informational websites, company websites, and product advertisements which 
are placed on every type of webpage imaginable.  Although the Internet is the 
one of the newest mediums for DTC advertising, it may soon become the 
frontrunner with “nearly 100 million Americans [using] the Internet to find 
health information” between September 2005 and September 2006 (“Pharma 
Companies’ Internet Marketing”).  The scope of DTC pharmaceutical ads is 
undoubtedly increasing at a tremendous rate with the increase in marketing 
efforts on the Internet alone, thus calling for a revision of current FDA 
regulations. 
 The regulations surrounding DTC pharmaceutical advertisements have 
been revised many times since the ads started to become a more popular 
marketing tactic and restrictions were imposed in the early 1980s.  The rules 
and regulations were only slightly revised over the next fifteen years, but the 
introduction of the FDA’s Modernization Act in 1997, brought forth more 
freedom for pharmaceutical companies that wanted to take advantage of DTC 
efforts.  Rules and regulations were relaxed and the market experienced a DTC 
surge that resulted in enormous profits for drug makers (White 232).  The 
increased presence of pharmaceutical ads re-fueled debate over the ethics and 
educational value of their use.  In order to determine the best regulatory 
response, the FDA initiated the three studies mentioned in Chapter 1 in order 
to determine whether or not the ads should continue.  The results prompted 
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the FDA to consider DTC ads not only educational, but also a good 
preventative tactic for everyday citizens.  The FDA asserts that drug ads are 
beneficial to the public, as long as certain requirements are fulfilled, “for such 
promotion to have this beneficial effect, it must be truthful, non-misleading, 
and scientifically substantiated” (Guidance for Industry…Print 
Advertisements).  Despite the research and data used to support this view, the 
debate over the effectiveness in patient education persists and the FDA 
continues to revise its regulations with more amendments promised very soon.   
 Pharmaceutical companies in the United States rely on the ability to 
market their products to consumers who will often pay a hefty price for a 
healthy lifestyle. Although companies spend a great deal of money to employ a 
sales force that markets products to physicians and pharmacists around the 
country, the primary target audience for US pharmaceuticals is citizens.  The 
industry spends enormous amounts of money on DTC advertising, allocating 
$1.9 billion dollars for the first five months of 2004 alone (“Drug Makers are 
Changing”).  Not only does the FDA regulate the entrance of new drugs into 
the market, it also provides rules for promotional efforts within the United 
States.  Although the FDA provides regulations for DTC advertisements, 
pharmaceutical companies are not required to submit ads to the FDA prior to 
their public release.  In fact, the FDA’s review process can take so long, that 
ads have often finished running on television or in print media before they are 
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even reviewed.  After the review process, the FDA issues warning letters to 
pharmaceutical companies that “misrepresent” their product in 
advertisements, often leading to legal action against the company (Jaramillo 
277).  Since regulatory action taken by the FDA can often lead to such legal 
matters, companies are encouraged to abide by current regulations. 
DTC Advertisement Types 
 According to the FDA, there are three main types of DTC 
advertisements: product claim, reminder, and help-seeking.  The most 
prevalent of these ads is product claim, where both the name of the product 
and an explanation of its use are provided to consumers (Figure 2.1).  The FDA 
requires that “claims of drug benefits, such as safety and effectiveness, must be 
balanced with relevant disclosures of risks and limitations of efficacy” 
(Woodcock).  If the information is in print form, companies must provide a 
“brief summary” of risk information that can typically be found in a product’s 
package insert (PI) (Figure 2.2).  This data, according to advertising regulations 
set forth in the Federal Food, Drug, and Cosmetic Act, includes all risk factors, 
contraindications, FDA approved medical studies concerning the medication, 
and side effects in addition to directions for use and product benefits 
(Guidance for Industry…Print Advertisements). Anyone familiar with print 
pharmaceutical ads has seen this information on the reverse side of the ad as it 
is often printed in miniscule text and is packed with industry specific 
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language.  Companies that use television commercials are required to provide a 
web address or phone number where consumers can obtain the same 
information (Woodcock).  The product claim advertising method usually 
reaches consumers in a very persuasive context that relies heavily on 
emotional appeals to promote the effectiveness of a product.  This strategy is 
often ridiculed because the advertisements print the side effects and potential 
risks associated with the drug in very small text sizes that are easily 
overlooked.   
 
 
Figure 2.1. Example of a Product Claim Advertisement, Crestor. Advertisement.  Prevention.  
June 2006. 
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Figure 2.2. Reverse Side of the Product Claim Ad Above, Crestor. Advertisement.  Prevention.  
June 2006. 
 
 The second type of pharmaceutical advertisement, the reminder ad, can 
mention the product name and “dosage form” (i.e., tablet, capsule, etc), but 
cannot provide any information as to what the product does (product 
indication) or when to use it (Figure 2.3).  Traditionally, reminder ads were 
directed towards physicians who already knew the name of the product and its 
recommended uses (Woodcock); however, the ads are now presented in 
magazines and on television where a general audience can be persuaded.  
Reminder ads cause a great deal of confusion amongst consumers since they 
provide very little information (Byrd-Bredbenner and Grasso).  Consumers 
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often determine the use of the drug based on visual cues that are present in the 
ads which can (and often do) lead to misinterpretation of the product’s 
intended use.  In turn, each member of the intended audience creates their 
own impression of the drug’s function which increases sales based on socially 
constructed ideologies.   
 
 
Figure 2.3: Example of a Reminder Advertisement Starring Dorothy Hamill, Vioxx.  
Advertisement.  Prevention.  January 2003. 
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 Although there are three types of drug ads, the FDA only regulates 
two: product claim and reminder. The third type, help-seeking, does not name 
a particular product, rather it briefly explains a disease or condition and 
encourages the audience to consult their physician for treatment or further 
information (Figure 2.4).  Recent examples include commercials for erectile 
dysfunction or overactive bladder problems (Byrd-Bredbenner and Grasso).  
According to Janet Woodcock, Director for the Center for Drug Evaluation 
and Research (a branch of the FDA), “because no drug product is mentioned or 
implied, this type of ad is not considered to be a drug ad and is not regulated 
by [the] FDA” (Woodcock).  Although help-seeking advertisements do not 
provide product names, the company who sponsors the ad is often listed or 
mentioned, thus pointing the consumer towards a company and its marketing 
goal.  
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Figure 2.4. Help-Seeking Ad Sponsored by Bristol-Myers Squibb, Cancer.  Advertisement.  
Newsweek.  1 November 2004. 
 
 Although these restrictions seem easy enough to follow, many 
healthcare professionals argue that the ads are deceiving and that they 
misguide patients, particularly older patients, into believing that they suffer 
from an ailment when, in fact, they may not.  DTC marketing techniques pull 
in a lot of money for the pharmaceutical industry in the United States and the 
FDA has firmly established rules that corporations must follow in order to 
advertise their products; however, since the FDA does not review the ads until 
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after they have already been released to the public, patients can suffer. This 
has caused several prominent drug campaigns to be stripped from magazines 
and television slots after brief exposure, but those that gain approval stay 
firmly in place, influencing an audience that often does not understand the 
medical jargon being thrown their way.   
FDA Regulations 
 The FDA places DTC advertisements into the categories of product 
claim, reminder ad, or help-seeking in an effort to establish precise rules and 
regulations for companies to follow.  Although grouping ads into such 
categories can help build an umbrella of guidelines for similar promotional 
tactics, regulating prescription products constitutes much more specific rules 
for the industry.  FDA rules and regulations can be categorized as follows: acts, 
code of federal regulations, guidance documents, and enforcement actions.  
Each category carries different legal limitations, thus some regulations carry 
legally binding guidelines and others do not. For example, an act is a piece of 
legislation that has been made into a law (“Act” def. Legislative act), whereas; a 
code of federal regulation (CFR) refers to “the general body of regulatory laws 
governing practice and procedure before federal administrative agencies 
(“Code of Federal Regulations” def.).  In the case of DTC advertising, legally 
binding regulations are primarily contained within the Federal Food, Drug and 
Cosmetic Act and 21 CFR 202.  Some of the most specific guidelines for DTC 
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advertising can be found in the FDA’s guidance documents, which are not 
legally binding.  In fact, the FDA specifically states that the documents “do not 
create or confer any rights for or on any person and do not operate to bind 
FDA or the public.  An alternative approach may be used if such approach 
satisfies the requirements of the applicable statue, regulations, or both” 
(Guidance Documents-About).  The Center for Devices and Radiological 
Health’s Division of Drug Marketing, Advertising, and Communications 
(DDMAC) works with “involved parties” to draft guidance documents in an 
effort to constrain DTC advertising with the most current goal being, to 
“[examine] whether the current advertising and labeling regulations should 
continue to apply to promotion directed to consumers, or whether there 
should be changes made in the requirements for this type of promotion” 
(Policy Development and Guidance).  Although guidance documents are not 
legally binding, pharmaceutical companies are encouraged to follow the 
guidelines in order to craft promotional materials that accomplish corporate 
objectives as well as federal objectives that are in place to protect the 
consumer.  Companies that violate the CFR or the Cosmetic Act receive 
warning letters from the Center for Drug Evaluation and Research (CDER), a 
branch of the FDA, as an enforcement action.     
 Although, I will more specifically address the compliance (or lack 
thereof) of DTC campaigns of statins with the range of FDA guidelines and 
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regulations in Chapter 4, I will now provide a glimpse into the language and 
specificity of guidance documents in order to provide readers with a basis of 
the language used to control DTC advertising.  The FDA differentiates 
between print and broadcast advertisements with the understanding of the 
impact each medium can have on a consumer audience. According to the 
FDA’s most recent “Industry Guidance” draft for print advertisements 
proposed in January of 2004, all DTC ads, regardless of type, should contain a 
brief summary of the product’s side effects and contraindications.  Known in 
the industry as the brief summary requirement, these guidelines provide the 
following options: 
(1) Present[ing] all risk information from the FDA-approved 
professional labeling; (2) reproduce FDA-approved patient labeling, 
either in its entirety or as modified to omit less important risk 
information; or (3) provide the risk information that would be 
appropriate for FDA-approved Highlights.  (Guidance for 
Industry…Print Advertisements) 
 
The first and second options refer primarily to the information that is included 
in package inserts that have been approved for either patients or healthcare 
professionals.  The third option, however, refers to a patient-friendly version 
of the same information, which alters industry specific language into a format 
more appropriate for the consumer as the audience.  Although the guidance 
document is not legally binding, pharmaceutical companies that wish to 
pursue an approach outside the scope of these suggestions are encouraged, but 
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not required, to submit alternative suggestions to the FDA before distributing 
the ads to the public (Guidance for Industry…Print Advertisements).   
Corporate Strategies and Implementation of Statins 
 Up to this point, I have discussed the debate surrounding DTC 
advertisements in the US and have provided a basic foundation of FDA 
regulations of consumer promotional efforts in the drug industry.  To put this 
information into perspective, a single product line within the pharmaceutical 
industry will be examined.  Statins, commonly known as cholesterol-lowering 
agents, are the largest selling prescription drug type in the world.  Although 
statins have been around since 1987, researchers continue to praise the affects 
of the drug, with Pfizer’s Lipitor leading the market.  Statins continue to be 
promoted to consumers through DTC advertising efforts, but the FDA does not 
have regulations specific to therapeutic areas.  All FDA DTC regulations are 
standard for every prescription product, regardless of type.  The uniformity of 
FDA regulations is an important fact to remember as the ethical analysis of 
DTC statin promotion is discussed in Chapter 4. 
 Pfizer’s atorvastatin, commonly known as Lipitor, was not always the 
leading statin in the cholesterol drug market.  Merck is credited with creating 
statins with the invention of lovastatin, commonly known as Mevacor, in 
1987.  This product line was created to battle high cholesterol levels in 
patients in order to help prevent heart disease.  Researchers and physicians 
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have identified several primary risk factors that can contribute to heart 
disease:  age, gender, heredity, diet, smoking, weight, and diabetes.  In order to 
determine whether or not a patient is at risk of heart disease, physicians use a 
test created by the US National Cholesterol Education Program (NCEP) that 
ranks individuals according to these risk factors.  For example, a man who is 
over the age of 45 is considered to be at risk for heart disease; however, a man 
of the same age who smokes and is diabetic has a much higher risk of heart 
disease and will most likely be encouraged to start taking a statin to help 
reduce or maintain lower cholesterol levels.  In addition to analyzing risk 
factors, doctors examine the levels of high density lipoproteins (HDL), or good 
cholesterol; low density lipoproteins (LDL), or bad cholesterol; and 
triglycerides (TG), a type of fat that is carried in the blood, to calculate a 
person’s current cholesterol level (Haines).  Generally, doctors recommend 
that a person maintain cholesterol levels below 200; however, a person with a 
high number of risk factors is often encouraged to maintain even lower levels.  
Although there are several options to treat high cholesterol, statins have 
become the drug of choice since they often lower LDL levels and increase 
HDL levels with a reduced chance of side effects than other treatment options. 
 Cholesterol drugs account for more consumer spending across the globe 
than any other prescription medication with revenues of over $25 billion per 
year for the corporations that produce them (Moynihan and Cassels 1).  
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Although Merck invented the first statin, Mevacor in 1987, and they 
introduced a second option, Zocor in the early 1990s, they were unable to 
maintain the rank of highest producer shortly after Pfizer launched Lipitor 
into the market in 1997 (Simons).  Pfizer exploded onto the market with a 
superior marketing tactic that included a lower cost and a centralized strategy 
that emphasized higher results with a lower dosage, a message that pleased 
physicians who were still hesitant to use high doses of a new medication.  
Lipitor became the second highest prescribed statin on the market, but Pfizer 
wanted to be number one.  In 1999, the company spent $55.5 million on DTC 
advertising resulting in a 40% increase in Lipitor sales in the first half of 2000 
alone (Posey).  Pfizer is now the nation’s fourth largest advertiser (Thomaselli 
and Sanders) and Lipitor is the world’s highest selling prescription drug ever, 
totaling yearly sales of over $10 billion (Moynihan and Cassels 3).     
  In 2005, Pfizer launched a new layout for product risk information 
that was intended to be more consumer-friendly because it reduced the 
amount of industry specific language commonly included in the package insert 
format and presented the information in a visually simplified manner (Figure 
2.5).  The changes were introduced to the DTC marketplace through the 
company’s most prominent product, Lipitor, “featur[ing] the prominent 
presentation of risk information [and] promot[ing] the drug as one of several 
treatment options including diet and exercise” (McGuire 30).  Since Pfizer’s 
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brief summary was introduced, many pharmaceutical companies have 
followed suit, using a similar format to provide consumers with product 
information and potential risks in a manner that is easier for everyday 
consumers to understand.  Pfizer’s format for providing risk assessment to 
consumers has been a breakthrough for DTC ads since medical jargon is 
presented in a reader-friendly format, a testament to Pfizer’s new mission to 
“support a productive patient-healthcare provider dialogue” (Arnold 30).   
 
 
Figure 2.5.  New Format for Product Information as Seen on the Reverse Side of a Recent DTC 
Ad, Lipitor.  Advertisement.  “USA Weekend.”  The Greenville News.  2-4 February 2007, 11-
12. 
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Much like other companies that promote statins, Pfizer has centered 
advertising efforts on product claim and reminder ads; however, as the most 
marketed product in pharmaceutical history, Lipitor has benefited from DTC 
campaigns with a primary focus on product claim advertisements.  The most 
recent campaign is recognized as the first time a physician has been used to 
promote a drug with Dr. Robert Jarvik, inventor of the artificial heart, 
appearing as the new spokesperson for Lipitor (Figure 2.6).   
 
 
Figure 2.6.  Product Claim Advertisement Featuring Dr. Robert Jarvik, Inventor of the 
Artificial Heart, Lipitor.  Advertisement.  “USA Weekend.”  The Greenville News.  2-4 
February 2007, 11-12. 
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 As of late November 2006, Pfizer spent an estimated $55 million on the 
Jarvik campaign (Schupak 52), a move that is credited with a 15 percent 
increase in Lipitor sales over the previous year (Bazell).  This is a profoundly 
effective endorsement as Dr. Jarvik is a familiar name in medical innovation.  
Examples of this DTC campaign can be found everywhere from popular 
magazines and newspapers to high traffic television spots.  Although many of 
the print versions portray Jarvik as a serious physician in his lab coat, the 
television commercial shows Dr. Jarvik rowing a kayak and sitting on the 
banks of a picturesque lake as he promotes Pfizer’s product with the words, 
“more cardiologists surveyed said they’d prescribe Lipitor for their own 
families than any other cholesterol brand” (qtd. in Arnold 30).  With 
groundbreaking DTC tactics including the utilization of a celebrity physician 
and a redesign of the product brief summary requirement, Pfizer continues to 
place itself at the top of the industry.   
 The success of Lipitor is an indication of the significant impact that 
DTC campaigns can have on a drug class.  It is easy to assume that medications 
that are promoted to consumers will enjoy higher sales than those that are not, 
especially when patients begin to ask their doctor for a prescription of a 
specific product, but the impact of DTC advertisements is much greater than 
one might assume.  When Pfizer invested a significant budget to DTC 
advertising of Lipitor in 1999, the sales of the product significantly increased.  
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Coincidentally, “between 1999 and 2000 the number of prescriptions 
dispensed for the fifty most heavily advertised drugs rose 25 percent, but the 
number dispensed for drugs that were not heavily advertised increased only 4 
percent” (Gahart et. al.).  DTC advertisements have a significant impact on the 
prescription habits of physicians as well as patient education.  Although the 
debate over the existence of DTC campaigns in the US continues to rage, 
pharmaceutical companies and the FDA must work to determine ethical 
strategies for DTC campaigns.   
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CHAPTER 3 
ETHICAL PARAMETERS OF PRESCRIPTION PHARMACEUTICALS 
 
The purpose of this chapter is to lay the groundwork for an analysis of 
the ethics surrounding DTC advertisements of pharmaceutical products.  
Scholars and theorists have attempted to define and set parameters for ethical 
decision making since the time of Aristotle and Plato and before, so 
establishing an ethical framework for the promotional efforts of the 
pharmaceutical industry is no easy task.  In order to assess the current ethical 
situation of DTC advertising, the parameters of business and advertising ethics 
must first be established.  The scope of the study of ethics is so broad that it 
would be overwhelming to discuss them all with relation to DTC efforts, let 
alone the pharmaceutical marketplace; therefore, this chapter will assess the 
most relevant concepts of ethics in relation to the referenced market in order 
to establish a list of norms for the purpose of this discussion.  Marketing 
pharmaceutical products is vastly different from promoting an everyday 
product such as chewing gum or laundry detergent because pharmaceuticals 
incorporate a more complex web of stakeholders.  In creating ethical 
parameters for marketing decision-makers in the pharmaceutical industry, this 
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chapter will lead to an assessment of current ethical trends within DTC 
advertising in Chapter 4, which will then turn to a proposal of changes in the 
creation of the ads in order to best achieve ethical codes of practice within the 
industry.  The overall goal of this chapter is to introduce the main overall 
concepts behind business ethics and then, to collapse these theories by relating 
them to the practice of DTC in the pharmaceutical industry.  Hopefully, this 
will make the ethics surrounding the ads easier to understand before a 
thorough analysis of the medical ethics of ads are cast into the mix.  By the end 
of this chapter, readers should understand the inner-workings of normative 
ethics as they pertain to prescription advertisements so that an ethical case 
study of statin advertisements, the purpose of chapter 4, makes sense. 
 Although the FDA has regulations for DTC advertising in place, 
decisions as to the use of language and the manner in which the marketing 
message is conveyed are the responsibility of a range of entities both inside 
and outside the sponsoring organization.  The overall goal of advertising is to 
encourage the audience the buy the marketed product; therefore, 
pharmaceutical ads are not just a form of public information.  DTC decision-
makers find themselves in an ethical dilemma: either provide a truly fair and 
balanced message that a varied audience can interpret and comprehend or 
cloud the message with medical terminology and persuasive strategies that 
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may encourage the audience to want a product without fully understanding its 
purpose.  Rhetorical theory can help determine ethics for DTC campaigns.      
 Determining ethical business decisions is not an easy task.  Ethics 
themselves are primarily social constructions that are based on an array of 
personal and professional ideals.  Professionals are faced with numerous 
ethical decisions within the corporate environment, not the least of which is 
determining the choice of language they will use when crafting a marketing 
message.  According to Mary Beth Debs and Kathryn Rentz, “to use language is 
to influence another person’s perceptions and values,” thus communication in 
any form is an ethical act (Rentz and Debs 37).  They argue that a flaw in 
business ethics is that it is often more concerned with how to act “ethically” 
rather than the audience’s perception of language.  Professionals have an 
“ethical responsibility” to control their use of language since their words will 
generate perceptions of the writer, in this case the pharmaceutical company 
and its products, and her message (Rentz and Debs 39). 
 DTC advertising is a rhetorical tool used by pharmaceutical companies 
to increase the sale of their products through persuasive techniques.  This goal 
coincides with the goals of a majority of technical communicators which 
Ornatowski asserts, have taken on a role of “irresponsibility” (Ornatowski 93) 
because a neutral, unbiased message cannot be created.  A DTC campaign 
cannot be created without placing greater emphasis on the interest of either 
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the consumer or the pharmaceutical company and, thus the question arises: 
how can an ethical advertising campaign be ethical?  Ornatowski uses the 
example of an aerospace engineer’s dilemma in reporting on the operation of 
an aircraft engine in accordance with environmental rules and regulations.  
While composing the technical report, the engineer must carefully evaluate 
language choice so that she truthfully reports malfunctions of the engine, 
while still protecting the interest of her employer (i.e., word the report in such 
a way that the malfunction is reported to customers, yet her employers will 
not fire her).  The engineer uses what Ornatowski calls “selective emphasis” 
(97), which is comparable to media spin, meaning that negative information is 
worded so that it does not sound as bad and vice versa.  The decisions of some 
DTC professionals to include selective emphasis in the campaigns are based 
upon their ideological relationship with pharmaceutical companies. 
 Ideologies held by executives in the DTC scenario are not the same for 
each employee or each corporation because, as Mary Beth Debs argues, “the 
society we participate in is made up of a proliferation of organizations, and 
part of the way in which we identify ourselves is made up of the multiple, 
often embedded, memberships we each hold” (Debs 161).  This is illustrated 
through the way companies dictate corporate authorship.  The person who 
writes a text is rarely identified as the author; instead the corporate logo takes 
ownership of the text.  If this is the case, then the person (or persons) who 
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create(s) an advertisement for a DTC campaign would not be viewed as the 
ethical decision-maker by consumers; instead the parent company would take 
the credit or blame.  Corporate authorship, which is commonly collaborative 
because of formatting suggestions and management revisions, is constructed in 
such a way that employees often do not realize that collaboration occurs: a 
situation that Bloom calls “anxiety of influence” (160).  Debs goes on to add an 
additional component to the traditional rhetorical situation (purpose, writer, 
audience) by distinguishing between “the corporation” and “the executive” as 
separate writers that are bound together through collaborative efforts (164). 
Although a marketing representative might compose a promotional piece, she 
must also gain approval from a manager or higher authority.  The writer must 
combine her own ideas and ethics with that of upper management and 
corporate goals.  Adding this extra component to the rhetorical situation 
makes the writer more of a “spokesperson.”  Since employees, and thus 
spokespersons, change in an organization, companies condition new hires to 
operate within the same constraints as the previous employee so that the 
audience does not have to adapt to changes.   
 In his analysis of ethics, Stuart Brown agrees with Henry Johnstone’s 
assertion that “most communication involves a social contract, one between an 
advocate and an audience” (qtd. in Brown 194).  Audience analysis is a vital 
component of any marketing campaign because companies want to make sure 
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that consumers will discover a need for the product through promotional 
efforts.  Ethics complicate the achievement of these goals and Johnstone’s 
statement further asserts that social construction is a factor in the 
determination of ethics.  He goes on to provide three requirements for ethical 
communication: “First, the advocate or writer must assume that audiences are 
beyond control…Second, both the writer and the audience must be open-
minded.  Third, both parties involved in the exchange must have a genuine 
interest in the outcome or the solution to the problem” (qtd. in Brown 194).  
Consumers for pharmaceutical products do have a “genuine interest in the 
outcome” as it pertains directly to their wellbeing (i.e., their health); but do 
pharmaceutical companies share this interest?  Of course the companies do 
want to help improve the health of customers, but money is usually the 
bottom-line.  Johnstone’s model of ethical communication may pose the 
biggest problem for companies that support DTC advertising of prescription 
drugs, especially in the eyes of physicians who are opposed to such efforts.   
 The impact that DTC advertising has had on the success of the 
pharmaceutical marketplace is undeniable.  With profound increases in sales 
since DTC ads were introduced into the prescription marketplace, it is evident 
that the campaigns work and continue to increase the number of consumers 
who are aware of medical ailments and possible treatments.  As discussed in 
the last two chapters, DTC advertising has endured escalating debate over the 
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past fifteen years with proponents advocating the increased consumer 
awareness generated by the ads and opponents insisting that the practice is of 
questionable ethics since the products are being promoted for profit.  The 
debate surrounding DTC campaigns raises a distinction between the pathos 
used in ads to increase company profits and the question of whether or not the 
advertisements include an element of logos that goes beyond patient 
awareness.  If DTC advertisements are meant to be a two-way mode of 
communication that encourage an increased knowledge of consumer 
healthcare awareness, then the ethical practice and nature of the ads needs to 
be discussed. 
Normative Business Ethics 
 When attempting to make ethical decisions in business, managers are 
faced with a wide range of ethical theories to dictate their course of action.  
For the purpose of this discussion of business ethics, only types of normative 
ethics (virtue, utilitarian, and deontology), which are centered on establishing 
rules or codes of conduct (Boylan 26), will be addressed.  Broadly speaking, 
each type of theory classifies the overall goal of the business that wants to 
make an ethical decision and proposes a solution; however, as will be 
illustrated in the following pages, each of the three categories of ethical theory 
can be broken down into more specific theoretical study and, not surprisingly, 
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theories are often combined in order to achieve what a corporation believes is 
the most ethical decision making procedure.   
In order to provide a consistent foundation for normative ethics, I draw 
the primary defining characteristics of virtue ethics, utilitarianism, and 
deontology from the works of Patrick Murphy and Joseph DesJardins.  
Murphy has conducted extensive research within business ethics and has 
received notoriety as a top marketing researcher, even serving as the 
marketing section editor of Business Ethics Quarterly.  He is also the co-
director of the Institute for Ethical Business Worldwide at Notre Dame 
University.  Murphy’s writings are used at universities all over the country in 
the teaching of marketing ethics.  DesJardins is the executive director for the 
Society for Business Ethics and has written a number of books that are used 
teach the fundamentals of business and environmental ethics.  While I utilize 
the parameters of normative ethics as discussed by Murphy and DesJardins, I 
also reference a few other theorists throughout this discussion of normative 
ethics in order to establish a solid foundation of theory.   
Virtue Ethics 
 Aristotle is credited as being one of the first authors of virtue ethics as 
an important model of moral decision-making, basing his argument on the 
idea of ethos.  Aristotle centered his study upon how individuals should live 
rather than what is considered a moral action (van Hooft 50).  He believed that 
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people cannot learn to be virtuous in the textbook sense, rather, they become 
virtuous through practice.  Every individual has ability to be virtuous, but each 
person must want to be virtuous in order to be so (van Hooft 58).  Rather than 
asking what can an individual do to be ethical, this theory encourages people 
to ask themselves how they should act (DesJardins and McCall 25).  A basic 
explanation of virtue ethics asserts that the values of the individual outweigh 
the values of the corporation when making moral judgments.  Three main 
elements guide the theory behind virtue ethics: 1) virtues are good habits and 
in order for them to work, they must be practiced and learned by everyone in 
the organization; 2) people learn to make admirable decisions because they 
witness others doing so; and 3) there must be a balance of virtuous practice 
(i.e., if someone is too truthful, they can be perceived as boastful) (Murphy and 
Laczniak 26-27).  Professionals should work on defining how to best apply this 
theory within a corporation, possibly even examining other companies that 
are considered to have high ethical standards.   
Johnson and Johnson is considered to be a pharmaceutical company 
with high ethical standards (Murphy and Laczniak).  This may be attributed to 
the way in which executives handled crisis management fifteen years ago, 
when the company voluntarily recalled all Tylenol capsules from pharmacy 
shelves nationwide after a small number of consumers in the Chicago area 
were fatally poisoned through bottles of the product that had been illegally 
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tampered with (Blackwell 21). Advertising campaigns were launched to 
increase public awareness and Johnson & Johnson destroyed their entire stock 
of tablets to promote good will and to show consumers that they were 
prepared to sacrifice their finances if it were in the best interest of the public.  
Despite their best efforts, the company did not avoid nationwide panic 
concerning the capsules, so they opened up a toll-free number service to help 
field calls from nervous consumers.  By the end of the first week, over 90 
percent of the American population had heard of the Tylenol poisonings 
(Blackwell 23).  Just a few years later, a similar incident happened and Johnson 
and Johnson was again credited as handling the situation in an ethical manner.  
Since the company reacted in such a manner, it is often cited as one of the 
most ethical pharmaceutical companies (Murphy and Laczniak; DesJardins and 
McCall; Gibson).  
 Theorists argue that it is the responsibility of the company to instill 
virtue ethics in employees.  Companies such as Johnson and Johnson have 
tackled this challenge by laying out values statements (not to be confused with 
a code of conduct) that outline the values of the company.  Johnson and 
Johnson may be successful in this model because the founders of the company 
instilled their values in the corporation from its inception and, thus, the 
practice of the values has been passed down throughout the years (Murphy 
and Laczniak).  The practice of virtue ethics within the corporate system could 
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be problematic in that it is difficult to establish or define what is good when 
the decision impacts an array of cultural backgrounds that may provide 
different definitions of what “good” is.   
This is further complicated by the notion that not all individuals have 
the desire to be virtuous, so achieving common ground may be impossible.  As 
with all ethical questions both the individual and corporation must choose 
between taking the “ethical” route or indulging in her or its own self interest. 
Virtue ethics proposes a solution to this dilemma: “Either we accept the 
inevitability of self interest and try to find ways to regulate it, or we look for 
ways to turn selfish interests into ethical interests” (DesJardins and McCall 25).  
The virtuous professional would have a desire to live ethically and, thus, 
would choose the latter approach.  The theory also poses a problem in that a 
virtuous practice is most often described as “for the good of the community” 
rather than singling out self interest (Murphy and Laczniak), thus, 
discouraging capitalist ventures where money is often the bottom line (Evan 
and Freeman).  Many businesses, Johnson and Johnson being a prime example, 
have incorporated virtue into their corporate strategy through the 
introduction and continued use of values statements which are meant to shape 
corporate culture towards ethical production.   
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Utilitarian Ethics 
 Although virtue ethics pose a valid normative ethical solution within 
the workplace, utilitarianism theory advances another option.  The primary 
premise for utilitarianism is the idea that decisions should be based on the 
consequences of actions; the best solution is the one which has the potential to 
produce the greatest good for all stakeholders.  A defining characteristic of 
utilitarian theory is that the consequences of an action must be able to be 
calculated, measured, and compared in order to assess possible positive and 
negative consequences (DesJardins and McCall), a task that is not always 
possible for every corporate decision.  One of the problems that surfaces with 
this theory is the lack of emphasis on the individual.  This theory leads to 
decisions which are based on the greater good rather than what is best for a 
single person.  When determining ethical solutions to business problems, 
companies typically encourage employees to make decisions that will 
emphasize the bottom line or financial gain of the organization.  This 
encouragement presents a dilemma because to achieve that objective places 
the goals of the company over an individual’s personal goals or ethics.   
In an effort to avoid such dilemmas, some theorists assert that social 
scientists, who are trained in specialty areas such as medicine, law, science, 
and education, should be in charge of analyzing whether or not a decision is 
ethical when defining public policy (DesJardins and McCall 28).  For example, 
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within the scope of pharmaceutical DTC campaigns, a utilitarian perspective 
might mean that officials from the FDA and leading physicians should be the 
only voice in the ethical debate over advertisements because they have a 
specified knowledge of the industry and the effect of the ads.  This contention 
can be problematic because of the complexity of relationships among 
stakeholder groups in the pharmaceutical industry.  Physicians, for instance, 
overlap stakeholder groups including FDA officials, corporate board members 
and advisors, and healthcare providers, thus; if doctors are decision-makers 
operating under the utilitarian perspective, conflicts of interest may arise 
which in actuality could prevent the greatest good from prevailing because the 
doctor may have to choose between the greatest good for his patients versus 
that of his ties to other stakeholder groups. 
Deontology 
 A contrasting theoretical perspective is represented by deontology, 
which places no emphasis on the consequences of an action, but encourages 
decision-makers to implement a set of universal rules that should be followed 
by all stakeholders (Boylan).  This perspective relies more on the logos, or the 
logic, behind ethical decisions rather than the ethos of virtue ethics or the 
consequences of utilitarianism.  In this sense, individual rights are the focus of 
this theory because the rights of others should always be respected (DesJardins 
and McCall 31).  Deontology posits that certain actions are inherently “good” 
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and the intentional ethics behind the decision is what should be considered 
rather than the consequences.  Russian philosopher Immanuel Kant, a leading 
proponent of deontology, is credited with developing three main 
characteristics that determine “appropriate” behavior in all situations:  
1. Act only on maxims that you can will to be universal laws of nature. 
(universality) 
2. Always treat the humanity in a person as an end and never merely as 
means. (never treat people as a means to an end) 
3. Act as if you were a member of an ideal kingdom of ends in which 
you were both subject and sovereign at the same time. (moral 
community)  (qtd. in Murphy and Laczniak 21) 
 
Kant contends that there are universal standards for ethical behavior; thus, and 
that the individuality of stakeholders should not be questioned per se because 
universal morality determines their ethics.  This approach differs greatly from 
the utilitarian view where stakeholders are seen more as tools in completing 
ethical tasks rather than as individual persons.  Kant also asserts that every 
rational human being, “exists as an end in itself, not merely as a means to be 
used by this or that will at its discretion; instead he must in all his actions, 
whether directed to himself or also to all other rational beings, always be 
regarded at the same time as an end” (Kant 18).  Even though this theory 
places more emphasis on the individual, it also proposes universal rules of 
conduct, which are difficult to establish when the stakeholder range is broad.  
Deontological ethics can be broken down into a vast number of categories 
ranging from religious affiliation to natural law; however, the role of 
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individual rights is most pertinent to the current discussion of business ethics 
because it falls in line with stakeholder theory (DesJardins and McCall 31). 
The Role of Stakeholder Theory 
The normative ethical practices of virtue ethics, utilitarianism, and 
deontology provide different moral models for business decision-making in a 
general sense, but in order for managers to determine ethical strategies for 
their companies, ethical parameters must be further narrowed.  Up to this 
point, the term stakeholder has been used in a general sense, but business 
ethics call for a more articulated distinction between stakeholders and 
shareholders in order to define the basis for stakeholder theory.  In general, 
shareholders, also referred to as stockholders, are the individuals who stand to 
financially benefit from an investment in an organization (i.e., the owners).  
The scope of a stakeholder expands from the narrow shareholder view where 
the only thing that matters is increasing financial gain for those with a 
financial stake in the company, to an all encompassing group that includes, as 
defined by R. Edward Freeman, “any group or individual who can affect or is 
affected by the achievement of the organizations’ objectives” (qtd. in 
Goodpaster 230).  Stakeholders can be further classified into two groups: 1) 
primary, which includes owners, employees, consumers, and affiliates such as 
suppliers; and 2) secondary, which includes the government, general public, 
competitors, and anyone else who may be affected by the actions and decisions 
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of the corporation (Boylan 79).  Primary stakeholders usually make a greater 
impact in decision-making since they have a more formal relationship to the 
company; however, secondary stakeholders also should also be considered 
when ethical decisions are in question (Figure. 3.1). 
 
 
Figure 3.1.  Diagram of Primary Stakeholder Groups in a Large Corporation, DesJardins, 
Joseph and John McCall.  Contemporary Issues in Business Ethics.  5th ed.  Belmont: Thomson 
Wadsworth, 2005. 80. 
 
The primary stakeholder groups depicted above offer a simplified grid 
of the relationships of different discourse communities within a generalized 
organization.  Identifying the stakeholder groups in pharmaceutical companies 
is more complex than the traditional model because so many people are 
affected by the products produced.  Where traditional stakeholder groups are 
classified into groups of primary and secondary in the traditional model, 
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pharmaceuticals often fuse the groups together because stakeholder 
communities often overlap.  Governing bodies such as the FDA will fit into 
primary stakeholder groups because the rules and regulations governing DTC 
advertising must be followed and adapted to best suit the so-called educational 
needs of consumers.  Competitors may fall into the primary category because 
the innovations of one pharmaceutical company may lead to advances by 
another, or discoveries may lead to product withdrawals if necessary.  The 
affects of these stakeholder groups change the dimensions of stakeholder 
theory for pharmaceutical companies because everyone is a potential 
consumer.  The products promoted by DTC campaigns are products that might 
be needed by consumers, rather than commercialized products such as 
clothing or household items that merely might be wanted by the audience.  To 
further elaborate, doctors join consumers as stakeholder groups that bisect all 
groups in the organization because these professionals often make up advisory 
committees as employees, regulation consultants in FDA hearings, partial 
owners, company managers, or even paid speakers by competitors (Figure 3.2). 
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Figure 3.2. Representation of Stakeholder Groups Within a Pharmaceutical Corporation.    
 
Recognizing the difference between shareholders and stakeholders is at 
the forefront of stakeholder theory where the ethical business manager is 
encouraged to recognize the impact of her decisions on all groups. The theory 
is further complicated because individuals can fit into more than one group 
entity.  For example, a marketing manager for Pfizer who has been prescribed 
Lipitor to help lower her cholesterol will fit into both the employee and 
consumer groups.  Much like other ethical theories, stakeholder theory can be 
further broken down, in this case, into three main ideologies: descriptive, 
instrumental, and normative.  As stated earlier, this discussion is focused on 
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normative strategies, so I will rely on a normative stakeholder approach which 
analyzes the reasons stakeholder claims should be considered in business 
decisions for moral reasons regardless of potential benefits to the company (R. 
Phillips 66-67).   Although normative stakeholder theory is the focus here, it is 
important to note that descriptive strategies focus on whether or not the 
claims of stakeholders are considered in business decisions, whereas 
instrumental approaches concentrate on the impact stakeholders can have on 
attaining business goals without emphasis on the morality of decisions (R. 
Phillips 66-67).  Since this discussion will rely on normative stakeholder 
theory, the normative strategies mentioned earlier in this chapter will now be 
collapsed into the stakeholder theory of marketing ethics in order to establish 
boundaries for the discussion of ethics within DTC advertising.  
The normative approach to stakeholder theory relies heavily upon the 
deontological model of business ethics discussed earlier, thus encouraging 
businesses to avoid treating individuals as tools, or as a means to an ends.  
Deontology theorists, such as Immanuel Kant, assert that people have the 
ability to distinguish between right and wrong and that the moral duty is to 
treat others as you would want to be treated (Murphy and Laczniak 21), much 
like the Golden Rule of childhood.  Stakeholder theory provides managers 
with a framework for decision-making that takes the moral standpoint of 
affected groups into consideration.  Deontology shapes stakeholder theory in 
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three main ways: “i.) Businesses have positive duties to stakeholders based on 
stakeholder interests; ii.) Stakeholder groups are distinct from individuals; and 
iii.) Duties are owed to stakeholders equally” (Gibson 249).  The first assertion 
points to the fact that all groups have different interests in relation to business 
actions; however, not all claims warrant action by the company.  For example, 
customers want products that are of high quality and low cost, but managers 
may recognize that creating a product of high quality may not be feasible at a 
low price.  This concept points to an important distinction between what is a 
moral right versus a personal want.  Businesses have a moral obligation to 
stakeholders to consider their claims, but not all claims warrant moral action.   
The second deontological basis for stakeholder theory posits that 
groups are composed of individuals, an assertion that can complicate the 
ethical model, especially if individuals are members of more than one group.  
This can lead to problems in distinguishing between ethical claims of an 
individual versus that of a stakeholder group.  Stakeholder theory combats this 
notion through the contention that, “for a group to have moral standing…it 
needs to have a culture which will survive the coming and going of any one 
person, and whether written or not, there will be a continuing ‘spirit,’ or set of 
shared understandings, which identify the group” (Gibson 252).               
 The final deontological approach to stakeholder theory brings the 
concept of authority or partiality into ethical consideration.  Stakeholder 
 58
 
 
theory is considered neutral because it does not place emphasis on one group 
of stakeholders over another; the values and perceptions of every group should 
be considered equally.  Where stockholder theories place emphasis on the 
maximization of company profits with little regard to social or moral 
obligations, stakeholder theory envisions business managers as monitors of the 
“health of the organization” who must balance sometimes conflicting views of 
stakeholders in order to achieve a decision that is both ethical and non-
detrimental to the company itself (Evan and Freeman 81).  If no emphasis is 
placed on one stakeholder group over another, then managers are placed in a 
dilemma when making decisions where groups have conflicting claims.  
Known as the stakeholder paradox, this concept questions whether it is more 
ethical to ignore stakeholder claims and advance the financial maximization of 
stockholders or to acknowledge all stakeholders since managers are faced with 
an impossible task of balancing the value of all claims (Goodpaster 240).  To 
subvert this contention, theorists emphasize the importance of the fiduciary 
obligation businesses have to  protect the well-being of the company, and thus 
the stockholders, while also working to protect the rights of stakeholders.  
Theorists assert that it is natural for human beings to have feelings of 
obligation (such as justice, gratitude, and indebtedness) towards others and 
such notions can be described as moral agents (Gibson 254).  If this is the case, 
then managers may have a hard time balancing the claims of competing 
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stakeholder groups in order to determine an ethical course of action because 
the viewpoint of one group does not necessarily outweigh the viewpoint of a 
different group. 
Stakeholder theory is an effective model for decision-makers in 
business to follow in an effort to set a moral framework for their company.  In 
order to implement this strategy, professionals are encouraged to take the 
following steps: 
1. Establish a list of stakeholders 
2. Classify stakeholders into primary and secondary distinctions 
and determine the stakes each group has within the company 
3. Determine the responsibilities the organization has to each 
stakeholder group (legal, economic, ethical) 
4. Identify conflicts between stakeholder values 
5. Determine the best response to the benefits and risks in the 
stakeholder claims with emphasis on compromise (Murphy and 
Laczniak 7) 
 
Although ethical decisions are not guaranteed if stakeholder theory is 
implemented, this is a step in the right direction.  The theory should be 
applied in all levels of the organization, not just on a corporate level.  Thus, 
stakeholder theory is an effective framework for decision-makers in the 
marketing profession as well.  As previously mentioned, within the DTC 
pharmaceutical marketplace, the stakeholder range is much more complicated 
than in many other business scenarios because the products being marketed 
affect the health or well-being of an individual.  DTC campaigns reach a much 
more complex web of stakeholders because the specialists that might 
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recommend an ethical strategy can take on the role of specialist and consumer.  
Stockholders, managers, and employees of a pharmaceutical company also may 
be consumers of the product.  Physicians and pharmacists that make up 
specialty boards in the FDA can also serve on boards of pharmaceutical 
companies in addition to undertaking the role of healthcare provider for 
patients.  The wide range of stakeholders in the pharmaceutical industry 
further complicates the ability to make sound ethical decisions for DTC 
pharmaceutical ads. 
Ethical Advertising Decisions 
 Normative ethics and stakeholder theory propose solutions for 
decision-makers to make moral judgments for a company in general, but 
decisions can be further complicated when the business is examined in a more 
segmented manner.  In this respect, adding advertising into the discussion will 
introduce a range of factors that advertising (and often, marketing) managers 
must consider within their field.  While ethical decisions may or may not 
come up that often in a normal business setting, ethics enters the discussion 
almost daily in the advertising sector (Drumwright 608).  Ethics enters the 
advertising workplace in such a dramatic way, that advertising itself has been 
criticized as being unethical, regardless of the product being promoted.  
Ethicists have debated the morality of advertising for years, but whether or 
not advertising should exist as a practice is not the point of this discussion.  
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The focus here, rather, is to analyze the practice of advertising to consumers in 
the pharmaceutical marketplace in order to determine whether or not DTC 
campaigns are ethical promotional strategies.  The question is not whether or 
not businesses should be able to advertise their products, but whether or not 
pharmaceutical products can ethically be advertised and, if so, what strategies 
drug companies should adopt in order to ethically promote their products.  In 
order to further establish parameters of ethics within the discussion of 
advertising, factors such as puffery, legal discourse, endorsements, and 
deception will be placed at the forefront of the conversation.   
 Since their conception, advertisements have been criticized as 
containing misleading or deceptive messages that can create a sense of false 
need within audience members and can lead to sometimes harmful demand 
(Drumwright 619)--a claim that parallels the debate over DTC pharmaceutical 
efforts.  Advertising has an uncontested affect on society’s perception of reality 
(though the type and quantity of the affect is debated), influencing culture 
beyond the influence ads have over buying habits (B. Phillips 111).  
Promotional campaigns socially construct norms in society that can be seen in 
everything from language use and fashion sense to the perception of 
cleanliness and beauty.  The impact of such messages on society has caused 
ethicists to question the morality of advertising campaigns through the 
distinction between behavior and desire as motivators.  Ads that are not 
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deceptive in nature serve the purpose of increasing the desire for a certain 
lifestyle and proposing a way of soothing that desire.  In this case, the 
consumer already has a certain amount of desire for the lifestyle in question 
whether they realize it or not (DesJardins and McCall 326).   
This proves to be an interesting notion because it places less emphasis 
on the behavior of the consumer (i.e., whether they buy the product being 
promoted) and refocuses attention on the ability of advertisements to create 
socially constructed norms.  The idea that advertisements mold the 
psychological desires and lifestyles of consumers introduces an interesting 
notion into the ethical debate because the goal of advertising would then be to 
increase consumer demand for a lifestyle, not a specific product.  If this were 
the case, competing companies that market a similar product could join 
together to promote a certain lifestyle and product names would be irrelevant 
because the desire for the product type would exist.  It is important to establish 
the purpose of advertising campaigns in order to determine whether messages 
are meant to control the behavior of consumers or to encourage desire, thus 
introducing the concept of deception.  Although deception can be 
unintentional, theorists argue that this does not decrease the impact or 
morality of messages.   
   The dichotomy between consumer behaviors versus desire poses an 
interesting ethical dilemma within the advertising profession, but it hinges 
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upon the notion of non-deceptive ad campaigns.  One of the primary ethical 
debates within the industry is that deceptive advertising is not easily 
identified.  In fact, scholars such as Daniel Attas make a distinction between 
deception and lying, asserting that deception can come to fruition through 
both visual and verbal means, whereas, lying is achieved only through 
language (Attas 50).  Furthermore, deception is a successful attempt to mislead 
the audience, but lying is merely an attempt to do so (Attas 50).  The Federal 
Trade Commission (FTC), the government body that typically regulates 
advertisements (except DTC ads which, as previously mentioned, are regulated 
by the FDA) classifies ads as deceptive when they include, “false 
representations, material omissions, and other deceptive acts or practices” 
(Drumwright 610).  Deceptive ads are discouraged in an effort to promote 
non-misleading information transfer to consumers; however, deception and 
persuasion are two different things.  
For example, diet-conscious consumers might be familiar with the 
deceptive powers of food labels that include: “light” or “reduced fat” qualifiers 
but, in fact, are not healthy food options.  This advertising tactic was 
discouraged by the Nutritional Education and Labeling Act of 1990, which 
forced companies to include nutrition information on all food products (Weiss 
175).  The FDA attempts to regulate deceptive advertising through regulations 
such as the brief summary requirement mentioned in Chapter 2.  Many 
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scholars and leaders within the advertising industry acknowledge that 
everyone expects ads to be somewhat misleading or deceptive; however, this 
does not acknowledge the contention that ads are of questionable ethics 
(McCall 334).  The morality of advertising campaigns lies in the “fact of 
generally practiced or tolerated negligence in conveying information in 
advertising that has harmful consequences” (Attas 56), rather than the 
perception of the audience.  Thus, the intention of the company that generates 
an advertising campaign is key. 
 Intentionality of companies is another aspect of advertising ethics that 
is often difficult to pinpoint, especially when marketing tactics such as expert 
or celebrity endorsements and puffery are accepted practices.  Ethics are 
questioned in endorsements when it is not clear if the spokesperson really does 
use the marketed product, a requirement that is sometimes difficult for 
regulating bodies to determine (Drumwright 615).  As will be discussed in 
Chapter 4, the use of experts to promote prescription products is a current 
marketing trend that is receiving criticism due to the intention of 
pharmaceutical companies to persuade consumers and possible conflicts of 
interest between the experts in advertisements and the messages they provide.  
Regardless, it is important to note the questionable morality of using 
celebrities or experts to endorse a product; however, the use of puffery in 
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advertising campaigns has incurred higher levels of criticism because of the 
difficulty in determining the intention to deceive.   
As defined by Ivan Preston in his analysis of puffery, the concept is the 
presentation of information in advertisements that depict a product in a 
positive light using “subjective opinions, superlatives, or exaggerations, 
vaguely and generally, stating no specific facts” (qtd. in Drumwright 611).  
Messages that utilize puffery contain true statements that are over exaggerated 
in an effort to maximize the impact of the ad campaign: for example, Merck’s 
used the tag line: “It’s Your Future.  Be There.” to promote Zocor throughout 
part of 2005 (Zocor).  No facts are stated in this claim, but the consumer is 
presented with the idea that if they do not use Zocor to lower their 
cholesterol, they may not be alive to witness their future.  Critics of the 
advertising strategy assert that overstated claims do not present an accurate 
portrait of a product because they cloud relevant information, and thus alter 
logical buying decisions (Drumwright 611).  The FTC contends that the 
practice is legal on the basis of caveat emptor (Let the buyer beware).  This 
notion is defended on the grounds that “reasonable” buyers do not rely on 
persuasive statements from the company selling a product; therefore, they are 
not deceived (Drumwright 611).  Advertising executives conduct in-depth 
research to determine the social wants and needs of consumers in order to 
develop ads that will respond to these desires (Arrington 349).  Puffery plays 
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into this by embellishing the desired lifestyle and asserting that a specific 
product is the key to achieving the best life.  Images are repeated over and 
over through television and print ads, causing consumers to confuse desire 
with need.   
 Analyzing the question of ethics within the advertising industry is a 
difficult task in and of itself, but adding the complexity of the pharmaceutical 
industry and all of the stakeholders involved further complicates the ability to 
make moral marketing decisions in DTC campaigns.  The purpose of this 
chapter was to introduce readers to the impact of normative ethics on business 
decisions, then to collapse those ideologies into the stakeholder theory of 
marketing ethics in an attempt to establish boundaries for the application of 
ethics within DTC statin advertising.  After receiving a brief foundation in the 
ethical considerations within advertising itself, readers should now be 
prepared for the deconstruction of DTC statin campaigns in Chapter 4. 
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CHAPTER 4 
THE IMPACT OF STATIN PROMOTION IN ETHICAL DECISION-MAKING  
  
 With so many ethical questions affecting the decisions of marketing 
managers, it is not surprising that executives who create DTC campaigns for 
pharmaceutical products are faced with so many challenges.  Determining the 
normative approach to business decisions can be complicated because 
professionals often follow a combination of theories; however, adding such a 
complex and overlapping range of stakeholders into the equation (doctors, 
consumers, managers, employees, etc) further complicates the ethics behind 
DTC advertisements because decisions must in addition to all the stakeholders, 
consider the medical implications of products.  For example, physicians must 
apply the ethical requirements of the Hippocratic Oath, a set of universal 
duties for doctors, to every interaction with a patient (Cornelius 103).  The 
mandatory application of these rules sets boundaries for individual decision-
making by binding physicians together as a group.  Thus, marketing managers 
might assume that physicians, as a group, hold the same opinion of DTC 
campaigns; however, each individual doctor may have a different 
interpretation of the Hippocratic Oath.  Differences in the application of 
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universal rules such as the Hippocratic Oath further complicate marketing 
managers’ ability to determine the standpoint of stakeholders as group entities.  
In order to provide the best analysis of DTC statin campaigns, I will 
utilize stakeholder theory as an umbrella for analyzing ethics in statin 
advertisements since the ads affect such a wide and complex web of 
stakeholder groups as discussed in Chapter 3.  It is also important to note that 
normative ethics cannot be cast aside because there are important factors that 
each type of normative ethics introduces into the discussion.  For example, 
stakeholder theory relies heavily on deontology by acknowledging the ethics 
of individual groups; however, each individual stakeholder group is comprised 
of individuals who will bring different standpoints to the issue, thus virtue 
ethics will come into play.  Conflicts of interest within the industry are an 
important issue in this respect.  Since this chapter will fuse the practice of 
DTC advertising with the aforementioned ethical parameters, I will provide a 
framework by analyzing the following features of the ads:  language use, visual 
rhetoric, approval and distribution issues, and conflicts of interest.   
 Although I have not dedicated a significant portion of the thesis to a 
direct discussion of medical ethics per se, this topic needs consideration and 
will also be woven through this chapter.  It is important to note that the 
constraints of DTC campaigns are distinct from other advertising efforts 
because they bring the dissemination of medical information to the forefront 
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of the discussion.  As previously mentioned, prescription products affect the 
personal health of consumers, a factor that is not usually associated with 
common consumer products such as cleaning supplies or clothing.  Thus, using 
business and advertising ethics to qualify DTC content is not enough for 
corporate decision-makers.  Medical ethics touch every stakeholder group 
affected by DTC campaigns, creating a further need for ad analysis.  Because 
medical ethics is such a large issue, encompassing much more than just the 
impact of DTC efforts, I will discuss several components that are most germane 
to this discussion.   Ethics specific to medicine that I am considering in this 
chapter include: conflict of interest among stakeholder groups, the use of 
medical language that is targeted to a general audience rather than healthcare 
providers, and the implications of corporate codes of conduct in combination 
with a physician’s obligation to uphold the Hippocratic Oath.        
 In general, ethical reasoning is the process by which decision-makers 
should analyze an ethical issue in order to produce a morally sound result.  
Marketing managers are often encouraged to use the following three steps in 
order to come up with an ethically reasoned decision: 1.) Determine the 
ethical implications that are in question by determining the causes and effects 
of actions; 2.) Establish the parameters of ethical standards (i.e., choose which 
ethical theories will shape the moral judgment); and 3.) Apply the ethical 
standards to the ethical dilemma in question (Murphy and Laczniak 14).  Up to 
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this point in the discussion, I have provided readers with both the moral 
implications of DTC advertising and the ethical parameters by which I will 
analyze the dilemma.  The purpose of this chapter is to critique the 
construction and dissemination of statin ads using normative and stakeholder 
theories in order to promote ethical reasoning, thus determining which aspects 
of the campaigns are ethical and which are not.  Once the problem areas are 
established, I will then propose strategies to remedy ethical conflicts in 
Chapter 5. 
Impact of Language in DTC Advertisements 
 The effectiveness of DTC statin advertisements has undoubtedly helped 
generate the worldwide, blockbuster success of the drug class.  With the most 
recent Lipitor campaign totaling an estimated $55 million (Schupak 52), it is 
evident that pharmaceutical companies recognize ads as a stimulus to increase 
profits.  Analyzing the content of such marketing efforts is no easy task.  Each 
ad crosses the desk of a wide range of professionals from marketing executives 
to FDA regulatory members.  Each stakeholder brings a different purpose and 
interpretation to the DTC ad, thus complicating the ability to determine the 
educational content and the persuasive nature of the text.  Put simply, DTC 
advertisements are a form of communication that are intended to persuade a 
designated audience (which includes members of each stakeholder group) to 
act in a certain way by purchasing a specific product.     
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The use and manipulation of language is at the heart of this discussion 
because the words used in an ad, which can be interpreted differently by 
stakeholder groups, comprise much of the ethical basis of the text.  Rhetorical 
theory posits that language and ethics are tied together or, in the words of Paul 
Dombrowski, “Contemporary rhetorical theory holds that language, and all 
knowledge constituted and mediated by language, always inescapably 
embodies, represents, and propagates a world view and therefore a system of 
values” (qtd. in Markel 17).  Because of the influence language has on the 
determination of ethics, I first want to discuss the verbal appeals of statin ads. 
 As mentioned at the end of Chapter 3, promotional campaigns have a 
profound impact on the lifestyle of citizens in society.  Consumers digest the 
information and images created by ads and, in turn, want to achieve the 
healthy lifestyle promoted in the campaigns.  Evidence of this desire can be 
found within the increasing number of prescriptions for statins that are 
written each year, that is, rhetorically, the actual medical or physical actions 
of the drug on a body part or system have been erased by a larger construct: 
one’s lifestyle.  As the number of DTC ads have increased, so have the number 
of prescriptions written.  Many physicians criticize this increase in demand for 
the drug, asserting that patients see an ad on television or in a magazine and 
turn to their doctors to request a statin to prevent high cholesterol rather than 
trying other treatment options.  While preventative measures such as an 
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improved diet, regular exercise, and stopping smoking are proven to be 
cheaper, safe, and effective non-drug interventions for patients, the 
availability of DTC ads and increased consumer awareness have made it 
possible for statins to be sold to everyone (Moynihan and Cassels 2-3).   
Marketers have a huge responsibility to deliver an effective sales 
message that will satisfy corporate goals as well as achieve ethical standards 
since over 80 percent of physicians are willing to prescribe the specific 
medication asked for (as long as no apparent medical risks are present) 
(Callahan and Wasunna 170).  I have previously shown that statin 
advertisements have successfully increased the number of prescriptions 
written for the drug class.  Since ads are proven to have an impact on 
consumer desire for a particular lifestyle, it is safe to say that DTC statin 
campaigns have effectively increased consumer desire for a “healthy” 
cholesterol level.  The success of statins have more than likely satisfied the 
financial goals of pharmaceutical shareholders (as least in the sense that profits 
continue to increase each year), but does the lifestyle portrayed in DTC efforts 
achieve the same success in relation to ethics?  I will now attempt to answer 
this question by analyzing the linguistic affect of rhetorical appeals found in 
statin advertisements, most specifically, the language used to attain the 
audience’s attention and to explain the benefits and risks of products. 
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Interpretation of Language and Healthcare Models 
Regardless of the product being promoted, deception is an issue that is 
often associated with the message conveyed and lifestyle portrayed in an 
advertisement.  Statin campaigns often use language that could be deemed as 
deceptive or inappropriate to generate a fear of death within the audience in 
order to push consumers to seek treatment or prevention (Moynihan and 
Cassels 14).  For example, a 2005 Zocor advertisement in Prevention (Figure 
4.1) depicts a middle-aged woman walking in the rain and using an umbrella, 
rain hat, waterproof boots, and a rain coat to protect her from the weather.  
The top of the following page proclaims in bold text, “Every day you protect 
yourself.  Are you doing enough to protect your heart?” (Zocor, Feb. 2005).  
The ad then presents several selling points concerning Zocor, starting with the 
assertion, “Heart disease is the #1 cause of death in women” (Zocor, Feb. 
2005).  The product claim ad does comply with FDA guidelines by presenting 
safety and benefit factors in balance with potential risk considerations as well 
as mandatory PI information, which is included on the reverse side of the 
advertisement (Figure 4.2).  Consumers are directed to further information via 
the Zocor website, a help line, and the advice of the patient’s physician.  So, 
does this DTC advertisement possibly breech any ethical stances?  Is it 
deceptive?        
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Figure 4.1. Advertisement That Utilizes Language to Create a Fear of Death From Heart Disease, Zocor.  Advertisement.  Prevention. 
February 2005.
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Figure 4.2. Reverse Side of Same Advertisement, Zocor.  Advertisement.  Prevention.  February 2005.
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First, the ad attempts to appeal to the conscience of consumers by 
insinuating that people often take precautions for daily activities as simple as a 
rainstorm, but not for issues as important as cardiovascular health.  As soon as 
doubt is introduced to the audience, the ad goes further to use the fear-of-
mortality strategy by providing a statistic that links heart disease to women, 
then to death.  Research indicates that fear appeals are an effective advertising 
strategy that can increase the pathos and persuasive nature of an ad, while also 
increasing the audience’s ability to recall the main ideas of the advertisement 
(Snipes et. al. 273).  DTC campaigns are well known for using emotional 
appeals to help persuade patient action, but does the use of fear appeals really 
allow the patient to come away from an ad with adequate medical 
information?  The use of this type of pathos may make the consumer aware of 
the ailment, but it may not facilitate a two-way communication where the 
patient actively participates in constructing knowledge from ad material.  
Thus, the emotional appeals of the ads are evident but whether or not the 
language present in the advertisement actually educates consumers rather than 
just increasing awareness is a big question.  So, is it ethical to use emotional 
appeals when the advertisements are often defended by pharmaceutical 
companies, the FDA, and some physicians on the basis of patient education or 
on logos? 
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Stakeholder theory requires that the ethical decision-maker analyze the 
impact of her decisions on all groups affected, in this case: physicians, patients, 
marketing managers and employees, owners, and the FDA.  The Zocor ad 
above complied with FDA regulations and also did not receive any warning 
letters from the regulatory group.  As discussed in Chapter 2, the FDA has 
conducted several studies to test the effectiveness and informational value of 
DTC campaigns, thus concluding that the efforts are worthwhile and 
beneficial to patients as long as regulations and guidelines are followed.  Since 
the ad in question did not violate any of these boundaries, it is safe to say that 
the FDA, as a stakeholder group, would most likely consider the ad to be 
ethical.  Marketing managers, owners, and employees would find that the ad is 
ethical for the same reasons with the additional assertion that market share 
increased.  Thus, Merck not only increased patient awareness, but also 
increased company profits.   
So far, all stakeholder groups are probably in agreement that the DTC 
ad is both ethical and effective; however, conflicting viewpoints might present 
themselves when physicians and patient stakeholder groups are taken into 
consideration because the individuals within each group will have a range of 
interpretations and opinions.  The introduction of differing opinions 
complicates the ethical decision-maker’s assessment of the problem if they 
choose to follow stakeholder theory. 
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Stakeholder theory relies on the classification of individuals into groups 
based on their social relationships and status in relation to the company in 
question, in this case, the pharmaceutical corporation.  Classifying people into 
groups, such as physicians and patients, allows the marketing manager to try to 
determine the ethical position of each group through conducting studies or by 
consulting a panel comprised of members of each stakeholder group.  
Although each group is represented in this scenario, little is said about how 
decisions are reached within the stakeholder group itself.  It is unlikely that 
everyday citizens are well versed in theories of ethics and that each individual 
has chosen a specific theory by which to live their lives.  In this respect, 
ethical theorists Reidenbach and Robin have introduced the notion that 
“individuals do not use the clearly defined concepts of ethical philosophies in 
making specific ethical evaluations, but that a mixing or combining of these 
philosophies is the norm” (Snipes et. al. 274).  Thus, in order to determine 
whether or not physicians and patients (as stakeholder groups) consider fear 
appeals to be deceptive or unethical advertising, normative ethics must be 
addressed. 
When assessing the value of normative business ethics in relation to 
DTC advertising of statins, it is important to note that ethical strategies are 
complicated by the dynamics of the healthcare system.  The three primary 
types of normative ethics as described in Chapter 3 included: virtue ethics, 
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utilitarianism, and deontology.  While virtue ethics are centered upon the 
individual’s quest to determine what is “good,” deontology and utilitarianism 
go beyond the individual and center attention on the organization.  Within 
the healthcare system, there are two primary structural models: 1.) physician-
focused, in which product information is provided to doctors who, in turn, run 
medical exams and tests for the basis of interaction with the patient; and 2.) 
patient-focused, in which the patient receives all information and has a greater 
role in healthcare decisions; the doctor exists to please the patient (Parker and 
Pettijohn 282).  These two structural models of healthcare also represent a 
valid parallel between healthcare professionals who adopt deontological 
standpoints versus those who prefer utilitarian strategies.   
For instance, a deontological perspective centers on the physician’s 
duty to her individual patient to provide ethical healthcare, whereas, the 
utilitarian perspective re-centers focus on the greatest good for the largest 
number of patients.  The deontological approach parallels the physician- 
model of healthcare because doctors uphold universal rules such as the 
Hippocratic Oath in an effort to facilitate trust within the doctor-patient 
relationship, thus becoming “the patient’s advocate, with the patient’s health 
being the physician’s primary concern” (Cornelius 103).  In this respect, some 
physicians may disagree with the use of fear appeals in statin (or any DTC) 
advertisements because the solution proposed by the ad is to prevent heart 
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problems by taking a specific cholesterol-lowering agent, in this case, Zocor.  
Here, the physician-patient relationship shifts more towards the patient, 
which is in contrast to this healthcare model.   
In fact, a study conducted in 1999, indicates that both physicians and 
patients “contend that DTC [advertising] alters consumers’ communication 
behavior, and, ultimately, relationships with physicians, by encouraging 
greater patient participation and control” (Cline and Young 1050).  In this 
respect, those who utilize a physician-model of healthcare would most likely 
discourage not only fear tactics such as the one referenced in the Zocor 
advertisement, but also the ad’s push to “Ask your doctor if Zocor is right for 
you” (Zocor. February 2005).  Even though the doctor-patient relationship is 
encouraged here, the rhetoric of the advertisement encourages the patient to 
initiate the medical discussion rather than the physician.  Thus, proponents of 
the deontological, physician-centered, healthcare model would most likely 
consider the linguistic strategies used to be unethical even if an ad causes a 
patient who “needs” the drug to consult their physician.  Since this healthcare 
model relies on a deontological approach, the consequences of an action (in 
this case, the patient’s response to the DTC ad) are not judged, but rather, the 
action itself is what matters (i.e., shifting responsibility from the physician to 
the patient is considered unethical).   
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Advocates of the patient-centered healthcare model fall under a more 
utilitarian perspective which would tend to see the consequences of fear 
tactics as a positive effect.  Under this framework, the greatest good is 
considered to be the most ethical standpoint and patients have greater control 
over their medical treatment in that they receive information on treatment 
options, and then they consult their physician.  In patient-centered healthcare, 
the doctor exists to please the patient, though they must still uphold standards 
such as the Hippocratic Oath.  In this system, physicians would judge the 
ethics of fear appeals in statin advertisements by examining the consequences 
of the ads on all patients as a group rather than an individual basis (Cornelius 
105).  Although the patient-centered model appears to suggest greater focus on 
the individual, decisions are still based upon utilitarian cost and benefit 
analysis to determine the greater good (Cornelius 105), so if patients consult 
their physician about an ailment (or product) mentioned in an ad, they have 
the potential to benefit from the medication if it is needed.  Without DTC 
efforts, some patients may not become aware of medical conditions and, thus, 
might not ask for treatment.  Because patients have the potential to medically 
benefit from DTC ads (through awareness), advocates of the patient-focused 
healthcare model might contend that the ads are beneficial.   
If decisions are created for patients as a group rather than on an 
individual basis, both the physician and the patient are put into a difficult 
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position.  As discussed in Chapter 1, 2002 FDA studies indicated that at least 
28 percent of physicians felt at least somewhat pressured to prescribe a specific 
drug when asked to do so (Woodcock).  More recent numbers indicate an 
increase to 80 percent of physicians who are willing to prescribe a specific 
medication requested by a patient, suggesting that physician compliance to 
patient demands is on the rise (Callahan and Wasunna 170).  With so many 
physicians prescribing the desired medications of their patients, it can be 
argued that DTC advertisements allow patients to become aware of ailment 
and treatment options and, in turn, patients can take charge of their health by 
asking for preventative measures.  In fact, DTC advocates assert that 
“consumers can engage in more equitable relationships with healthcare 
providers and become partners in their own healthcare as a result of DTC 
[advertising]” (Buckley 5), which coincides with the goals of the utilitarian 
patient-centered healthcare model.  Some might argue that patients are tools 
of the pharmaceutical industry because they are persuaded by fear appeals and 
the healthy lifestyle presented in DTC ads to ask for a specific medication, a 
utilitarian perspective would probably assert that the patients who benefit 
from the ads promote the greatest good scenario.  Statin ads, such as the Zocor 
piece above, use fear appeals as a stimulus to push consumers to consult their 
physician about cholesterol problems, a tactic that increases patient education 
and thus could be deemed ethical from a patient-focused healthcare approach. 
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 Based on the current analysis of fear tactics in DTC statin 
advertisements, the practice will most likely be deemed as ethical by all 
stakeholder groups except physicians in the physician-centered or 
deontological healthcare model.  Since evidence shows that fear appeals 
increase interest in the product advertised without introducing deception, the 
tactic proves ethical and beneficial in the eyes of the FDA, members within 
the pharmaceutical corporation, and to consumers (especially since the drugs 
are prescription products, thus, professional medical advice and support is 
needed).  Even though the practice is ethical in the eyes of a majority of 
stakeholders, ethical decision-makers who wish to follow the stakeholder 
theory of ethics are now caught in the paradox, with no clear solution because 
all stakeholders are not in agreement. 
Package Insert (PI) Information 
Fear tactics and deception are only two of a wealth of rhetorical 
strategies used by marketing managers to utilize language in DTC 
advertisements.  Although these are typically the most controversial measures, 
it is also important to discuss the use of medical language in the ads in relation 
to audience perception.  DTC campaigns utilize the persuasive nature of 
language beyond the obvious sales message of an advertisement.  PI 
information must be provided for every product claim ad.  Here, I will 
examine the difference in comprehension between the linguistic rhetoric of 
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traditional PI information provided in DTC statin advertisements versus the 
new format created by Pfizer in 2005.  In the next section, I will discuss 
differences in visual context. 
The traditional PI model provides prescribing information that is 
approved by the FDA before a drug is launched.  The information included is 
directed at a range of individuals including: prescribing physicians and 
pharmacists who will use the text to educate themselves on the features, 
benefits, and risks of the drug; patients who will use the information to learn 
about a product they have been prescribed; and consumers who see the 
information on the reverse side of DTC advertisements.  The text is divided 
into several headings including (in this order): “Contraindications,” 
“Warnings,” “Precautions,” “Adverse Reactions,” and “Overdosage.”  The 
traditional PI is often disbursed with prescriptions and was used years before 
DTC advertisements of prescription products entered the market thus 
originally, the general public was not the intended audience for package 
inserts.  Conversely, Pfizer’s new PI information is geared towards a general 
audience and was constructed solely for use in advertisements.  This 
distinction is made clear since the document is titled “Important Facts” rather 
than “Prescribing Information.”  The major headings of this PI include (in this 
order): “Lowering your Cholesterol,” “Who is Lipitor For,” “Before you Start 
Lipitor,” “About Lipitor,” “Possible Side Effects of Lipitor,” “How to Take 
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Lipitor,” and “Need More Information.”  A comparison of the PI headings 
alone proves that the new model includes much more simplified language that 
can be understood and utilized by everyday consumers.  The new format is 
much more user-friendly and provides information in a way that is fairly clear 
to a general audience; however, it is important to note that the PI may not 
fully educate consumers but, rather, it provides information in more accessible 
language for the target audience.    Although Pfizer launched this new format 
for product information, other pharmaceutical companies are now following a 
similar format.  Which model should marketing managers choose to 
implement? 
In order to determine the ethics of disseminating medical information 
through PIs, medical rhetoric and the complexities of language must be 
examined.  Medical language is often difficult for the public to decipher, even 
prescription drug labels.  A recent study shows that “only 34.7 percent of the 
people with lower literacy, grade level or below…could determine the number 
of pills to take daily when faced with ‘take two tablets by mouth twice daily’” 
(Edelson “Prescription”).  The study went further to assert that many people 
with higher literacy, including individuals with college degrees, have trouble 
understanding such instructions (Edelson “Prescription”).  If the public has 
this much trouble understanding directions on how to take a medication, what 
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does that say for the contention that patients can educate themselves from 
DTC advertisements? 
When comparing the two types of PIs, it is evident that the new 
version is much more reader-friendly.  For example, one of the possible side 
effects of Lipitor is worded, “Muscle problems that can lead to kidney 
problems, including kidney failure.  Your chances of muscle problems is 
higher if you take certain other medicines with LIPITOR” (Lipitor Greenville 
News).  By using simple language and avoiding high levels of industry specific 
language, the PI delivers a message that should be clear to most audience 
members.  Although the same information is included in the traditional PI, it 
is scattered throughout the text and is stated in much more scientific language.  
For example, the same side effects are listed under “Adverse Reactions” and 
further categorized as “Urogenital System.”  Instead of using simple sentences 
and language to inform consumers that kidney problems may arise with the 
use of Lipitor, the traditional PI lists possible kidney problems among other 
potential issues within the urogenital system, “Urinary tract infection, urinary 
frequency, cystitis, hematuria, impotence, dysuria, kidney calculus, nocturia, 
[etc.]” (Lipitor Prevention).  The difference between the two types of package 
insert can be simplified into the concept of audience.  The traditional model is 
targeted towards people in the healthcare industry who have a heightened 
understanding of medical language, so they have the ability to respond to the 
 88
 89
text where consumers do not.  The new PI simplifies language into a more 
accessible format that allows anyone to fit into the audience label even though 
true patient education may not arise.  Going further, the traditional model uses 
scientific language to convey very precise, logical, and accurate prescribing 
information; however, professionals write this text for the FDA before the 
drug is even launched.  A single, traditional PI is written for the FDA and is 
not altered for a more diverse audience after FDA approval is received, a 
“rhetorical constraint” that is now conquered through the availability and use 
of the new PI (Bell, Walch, and Katz 252).  Given the range of audience 
members that can use the new PI format versus the narrow window of 
comprehension for the traditional version, it is safe to say that all stakeholder 
groups would assert that the new model is the most rhetorically ethical for use 
in DTC efforts.   
Visual Rhetoric 
 Language use is an important element in DTC advertisements because 
marketers carefully choose words to convey a specific message to consumers.  
While the ethical implications of language use is key in analyzing DTC statin 
campaigns, visual rhetoric also plays a very important part in determining the 
intentions of promotional efforts.  In a general sense, ad campaigns are 
considered effective (in the eyes of shareholders and the advertising industry) 
if they successfully persuade an audience to buy a specific product by creating 
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a message that is meaningful to the audience, creating a lasting image.  
Advertisements do so through impacting the audience, “by achiev[ing] the 
appropriate synthesis of primary visual and secondary verbal elements 
mutually reinforcing one another; the perceptual reception of the message is 
determined by the set of thoughts and emotions that are part of the consumer” 
(Barry 254).  The audience sees the visual aspects of an ad before they begin to 
digest any verbal messages; thus the visual impact of DTC statin 
advertisements is a critical element in the discussion of ethics.  Marketing 
executives consider every visual component of an advertisement; therefore, 
every aspect of an image is “intentional” (Barthes 152).  In order to keep the 
scope of the discussion of ethics within DTC statin campaigns at a reasonable 
level, I will now analyze the use of graphs and charts, font size and placement, 
pictures, and celebrity or expert endorsements within DTC ads.  
Font Size and Placement 
 Consumers are often encouraged to read the small print when assessing 
the validity of a contract; the same is true for the validity of claims presented 
in a DTC ad.  Very often, pharmaceutical marketers satisfy the FDA’s brief 
summary requirement (that must provide risk information) by printing the 
information in very small typeface.  Although many ads mention a couple of 
risk factors on the first page (of a print ad) or in small text at the bottom of the 
screen (for a television ad), most of the mandatory risk information is 
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presented in the PI.  As previously mentioned, the new format for PIs is much 
easier for consumers to understand because the complexity of medical rhetoric 
has been simplified for a general audience.  The same is true for the format of 
the new PI.  The original format for PI information consisted of extremely 
small text with little or no format changes to denote sections of information 
such as side effects, indications, dosage forms, etc (Figure 4.3).  The new 
format utilizes varied text sizes with the smallest still being large enough to 
read (Figure 4.4).   
 
 
Figure 4.3.  Actual Size of a Portion of Traditional PI Information on the Reverse Side of an 
Advertisement, Lipitor.  Advertisement.  Time.  5 August 2002. 
 
 91
 92
 
Figure 4.4.  Scaled Down Portion of New PI Information on the Reverse Side of a Recent 
Advertisement for the Same Product, Lipitor.  Advertisement.  “USA Weekend.”  The 
Greenville News.  2-4 February 2007. 
 
In addition, sections of information are clearly separated and main 
points are denoted by bullet points.  Instead of a white background with black 
text, the new format also uses grey and bubbles to separate information, thus 
making the material more reader-friendly.  It is likely that more consumers 
will read the new format because of the stylistic changes, whereas, the 
traditional model might be skipped because the text is so small.  Pfizer, creator 
of the new format, asserts that visual and textual changes “make its ads more 
effective at communicating risk and benefit information and reinforcing 
doctor/patient relationships” (McGuire 30).  Some stakeholder groups might 
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disagree by asserting that the simplification of product information may not 
necessarily be ethical because all possible risks and side effects of drugs are not 
listed regardless of the visual simplicity of the text; however, analyzing the 
ethics of DTC ads through a visual lens goes beyond the words on a page and 
brings forth the initial response of a potential reader of the text.  That is to say, 
consumers do not have the potential to benefit from package insert 
information if they do not read it, and they will not read it if they do not 
respond to the visual composition of the text.  John Trimbur, a scholar in 
cultural literacy, asserts that the key to this response is in the typography of a 
text which, “call[s] attention to how the look of a page communicates meaning 
by treating text as a visual element that can be combined with images and 
other nonverbal forms to produce a unit of discourse” (Trimbur 267).  Thus, 
the new format of the PI has a greater chance of opening a discourse between 
the reader and the text of the statin advertisement because the larger typeface 
and clear layout is more visually appealing.  Engaging the text allows 
consumers to be more informed, while also facilitating further discussions 
with their physician; therefore, both the patient and physician models of 
healthcare should be satisfied, making it more likely that all affected 
stakeholder groups will deem this change as a step in the ethical direction. 
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Charts and Graphs 
 Many DTC statin advertisements also use the visual rhetoric of graphs 
and charts in order to illustrate the efficacy and superiority of a drug.  The use 
of graphs and charts to present scientific information is a common rhetorical 
strategy used to instill confidence in the information being presented.  In his 
case studies of the cholera epidemic and the Challenger disaster, Edward Tufte 
asserts that graphs and charts present a visual representation of information 
that can be misleading if the logic of the design behind the graph does not 
coincide with the logic of the quantitative data (Tufte 53).  He goes further to 
claim that appropriate cause and effect relationships as well as appropriate 
comparisons must be present in the design of graphs in order for the message 
to be clear and useful (Tufte 53).  DTC advertisements are known for using 
graphs or charts to present benefits over competitors or even to downplay the 
potential risks of a drug.  This advertising strategy is credited with instilling 
credibility in the audience, “and based on the perceived scientific precision of 
an abundance of charts and graphs included, [consumers] assume a far less 
skeptical orientation toward such information-rich advertising” (Beltramini 
334).  For example, the most recent statin to hit the market, Crestor, utilizes a 
graph to illustrate the results of a clinical study that proved that a 10mg dose 
of Crestor lowered LDL (bad cholesterol) levels at least 9 percent more than 
competing products (Figure 4.5).      
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Figure 4.5.  Portion of a Crestor Advertisement That Utilizes a Graph to Present Some of the 
Findings of the STELLAR Clinical Study, Crestor.  Advertisement.  Newsweek.  1 November 
2004. 
 
At first glance, the graph clearly proves that Crestor is the most 
effective statin on the market; however, the ad does not distinguish between 
statin and superstatin, leading consumers to believe that Crestor is the same 
type of drug as Lipitor, Zocor, and Pravachol.  The picture indicates that the 
10mg dose of Crestor reduces LDL levels 9 percent more than the same dosage 
of Lipitor, the most prescribed and recognized statin on the market.  What the 
graph fails to mention is that the superstatin status of Crestor means that “its 
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lower doses have the pharmacologic effect of the midrange doses of market 
leader atorvastatin (Lipitor-Pfizer)” (Bennett).  To an audience with a limited 
knowledge of statins, this point may not mean much (and might even be taken 
as an uncontested positive feature of the drug); however, the distinction 
between statin and superstatin is a big one to healthcare professionals because 
the latter is a relatively new form of a statin that has drawn consistent safety 
concerns.   
In 2005, the American Heart Association released information claiming 
that Crestor had a higher rate of adverse side effects than other statins on the 
market (Edelson “Crestor”).  While cardiologists assert that the drug is still 
safe, some assert that “it might be preferable” to try to lower cholesterol levels 
with traditional statins first and use superstatin Crestor when patient LDL 
levels are not efficiently reduced (Edelson “Crestor”).  Patients who are treated 
with statins are often prescribed a low dose with the potential to increase the 
dosage if a physician is not satisfied with the lowering of LDL levels.  Since 
some cardiologists encourage colleagues to prescribe the superstatin if a statin 
does not work, it is clear that the low dose of Crestor presented in the graph 
above is, in fact, not comparable to the lowest dose of Lipitor.  Although the 
graph in the Crestor ad above does present the findings of a scientific study, 
the information misleads consumers into trusting that the product is superior 
to other drugs in the same class.    
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If the primary goal of a DTC statin advertisement is to encourage 
patients to be aware of the dangers of high cholesterol and the possible 
prescription treatments available, the Crestor graph appears to satisfy the goal 
by showing results for each brand.    In light of this point, some physician and 
consumer groups will probably consider the use of graphs and charts to be 
ethical since the data shows the range of LDL reduction for starting doses of 
prescription treatment options.  The FDA did not issue a warning letter for 
this advertisement and, thus, did not consider the information to be deceptive.  
However, the ad is somewhat deceptive because it leaves out the difference 
between statins and superstatins.  Although the text above the ad which states, 
“Cholesterol high?  Trouble getting it low?  Perhaps your answer is right here, 
below.” does suggest an alternative prescription for patients who are already 
working to lower their cholesterol (Crestor), the combination of verbal and 
visual text presents a heightened argument for patients to alter current 
treatment to a different product, a persuasive strategy that could be deemed as 
unethical by some individual stakeholder members, especially those who 
ascribe to the physician-focused healthcare model. 
Celebrity Endorsements 
 A final visual component that is of importance in statin ads is the use of 
celebrity or expert endorsements.  Statin advertisements have included a range 
of celebrity endorsements to appeal to various audience types including a 1999 
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campaign by Zocor which used NFL coach Dan Reeves (Henderson).  Silvia 
Bonaccorso and Jeffery Sturchio of the British Medical Journal assert that 
consumers are well aware of the persuasive nature of DTC advertisements, 
“But it seems condescending to assume that consumers have no consciousness 
of these mixed motives and that their skepticism will be dissolved in their 
anxieties about health and illness” (qtd. in Segal 34).  While consumers might 
already be wary of a celebrity endorsement, expert endorsements can still be 
more deceptive.  Advertising ethics require that expert endorsements must “be 
based on the actual use of the expert’s knowledge” and that the product points 
being delivered “must be within the endorser’s expertise” (Drumwright 616).     
Take for example, the most recent Lipitor advertising campaign in 
which Dr. Robert Jarvik, who is credited with inventing the artificial heart, 
encourages people to ask their doctor about the statin (Figure 4.6).  The 
argument is compelling; a well-known physician who significantly advanced 
cardiovascular medical technology by developing the artificial heart is bound 
to satisfy the credibility test of even the most cynical critic.  A closer look at 
the CV of this industry leader introduces some interesting points.  Dr. Robert 
Jarvik did not take the traditional route to earn his medical degree.  He earned 
his bachelors degree from Syracuse University, but his poor grades kept him 
from going to medical school, so he ended up graduating from New York 
University with a master’s degree in medical engineering (Bazell).  Upon 
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graduating, Jarvik began working with Dr. William Kolff, inventor of the first 
dialysis machine, who also happened to be working on an artificial heart 
(Bazell).  Jarvik used his engineering knowledge to alter the design of the 
heart, creating a device that lasted a record three weeks (Teague 61).  With 
groundbreaking medical technology on his side, Jarvik was finally accepted 
into medical school and he earned his medical degree in 1976 from the 
University of Utah (Bazell).  After receiving his medical degree, Jarvik 
continued to work on mechanical heart pumps under the supervision of Dr. 
Kolff, rather than practicing medicine (Bazell).  In fact, Jarvik has never taken 
an internship or practiced medicine (Bazell).  Instead, he continues to advance 
research in the use of the artificial heart with the hope for eventual FDA 
approval.  Jarvik credits this focus on invention to biomechanical leader Dr. 
Robert Fusom, “He became my role model for a physician who could devote 
his professional life to industry rather than clinical practice” (qtd. in Teague 
61).  Since earning his MD, Jarvik has continued to advance the success of the 
artificial heart with his most recent model, the Jarvik 2000, still in clinical 
trials. 
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Figure 4.6.  Portion of One of the Print Advertisements in Which Dr. Jarvik Advocates the 
Use of Lipitor to Prevent Heart Disease, Lipitor.  Advertisement.  “USA Weekend.”  The 
Greenville News.  2-4 February 2007. 
 
Although consumers are typically hesitant to believe everything they 
see and hear in a DTC advertisement, the notoriety of Dr. Jarvik packs an 
effective punch.  The ads have been so effective, that Pfizer saw a 15 percent 
increase in sales of Lipitor versus the figures from the same quarter a year 
before (Bazell).  The ethical dilemma that arises in using Dr. Jarvik is one of 
perceived credibility.  Although he undoubtedly has a superior understanding 
of the cardiovascular system, he does not have the same experience with 
patients that a cardiologist has.  Physicians who frequently interact with 
patients will have a better idea of how a drug will affect different patient 
types.  They will know what treatment options work best and will, most 
likely, have a better understanding of the common day-to-day health obstacles 
that face a patient.  While Dr. Jarvik undoubtedly has a superior knowledge of 
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the workings of the heart, his lack of clinical practice experience tarnishes his 
credibility as a physician promoting a statin to patients because he does not 
have the same doctor-patient relationship as a practicing physician.   
Despite the ethical problems with using Dr. Jarvik as a sponsor for 
Lipitor, the notion of the celebrity doctor poses another threat.  Medical 
ethicist Katie Watson of Northwestern University asserts, “The danger of 
celebrity physician ads is that it creates a physician figure that is in 
competition with my physician” (qtd. in Schupak 52).  In this respect, the 
word of one physician may be valued over another, a problem that could cause 
some patients to value celebrity advice over that of their own physician, who 
knows them and their medical history well.  Although corporate stakeholder 
groups and some physicians will see the use of medical celebrities as beneficial, 
the practice has definite ethical problems.      
Ethical Challenges within the FDA Approval Process 
 Now that I have analyzed some of the visual and verbal aspects of DTC 
statin campaigns, I will now discuss the FDA approval process that each 
campaign goes through.  As is explained in Chapter 2, the FDA is in charge of 
regulating DTC advertisements within the pharmaceutical industry.  
Regulations and guidelines are established in an effort to control the 
persuasive tactics used by pharmaceutical companies and to promote patient 
education.  If the regulations are not met, then the FDA issues a warning letter 
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to the offending corporation encouraging corrective action.  Technically, if 
corrective action is not achieved, the FDA has the right to cease the 
dissemination of the drug and to ban it from the market.  Although the FDA 
claims that all warning letters have been complied with to date (Gahart et.al.), 
several ethical dilemmas arise from this system.  First, DTC advertisements are 
not assessed until after they are already on the market and the FDA regulatory 
process takes so long that the ads have often run their course before corrective 
action is suggested.  This means that the FDA process takes so long, that by the 
time regulatory officials recognize that action is needed, the pharmaceutical 
company has already launched a new ad campaign (Pear). 
 The fact that DTC advertisements are not reviewed until after they are 
viewed by consumers introduces an ethical problem that is in dire need of a 
solution.  From a stakeholder standpoint, the risk involved in exposing 
consumers to ads for prescription products such as statins is alarming.  As 
previously mentioned, the linguistic and visual rhetoric presented in ads that 
pass regulations can still be of questionable intent such as the use of celebrity 
doctor endorsements, charts and graphs, or even fear appeals and deception.  
DTC advertisements deal with products that can have an adverse affect on a 
person’s health, thus a clear and ethical message is imperative.  Corporate 
pharmaceutical executives and owners might contend that any breech in FDA 
regulations was unintentional which, even if true, does still not compensate 
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for any damage already done.  Physician stakeholders might contend that 
misleading advertisements cause consumer panic or self diagnosis, thus further 
proving that regulations must be observed.  With the increased number and 
methods of DTC pharmaceutical advertising, it is quite possible that the FDA 
does not have enough resources (including employees) to review ads; however, 
this does not make current procedures ethical.  So how do stakeholder 
positions break down on a normative scale? 
 Individuals within stakeholder groups who lean more towards the 
utilitarian perspective would question the FDA timeline in terms of the greater 
good; however, it would be very difficult (if not impossible) to calculate 
whether or not specific patients were negatively affected by a specific 
deceptive advertisement.  Deontologists on the other hand, would assert that 
disseminating DTC advertisements, which are already a topic of questionable 
ethics, to the public is an unethical action regardless of the positive or negative 
consequences which may ensue.  Although no specific figures are available for 
the impact of the FDA ad review process of statins, 88 warning letters were 
issued by the FDA between August 1997 to August 2002 for prescription DTC 
advertisements (Pear).   
 Although the number of warning letters issued over a five-year period 
is small in relation to the number of DTC ads that run each year, it is also 
important to note that the FDA has no way of insuring or verifying that it 
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receives and reviews all new drug advertisements (Gahart et. al.).  In a system 
that relies on the FDA to regulate the content of all advertisements, this lapse 
opens the door to ethics problems in DTC advertising.  If the ad is reviewed 
and gets a warning, the drug can be stripped from the market if the parent 
company does not comply with corrective action.  This action creates another 
ethical issue.  The FDA could find itself in a dilemma because if the drug is 
stripped from the market, it is very likely that patients could suffer physical 
harm and even death.  For example, a Lipitor ad dispersed in 2002 received a 
warning letter stating that it “inaccurately claimed that Lipitor may not have 
the side effects of other statins” (Simons 61).  Although Pfizer did take 
corrective action by changing the wording of the ad, if they had not, then the 
FDA had the right to strip Lipitor from the market.  What impact could this 
have had?  Although the FDA claims that all warning letters issued on behalf 
of DTC problems have been successfully addressed, the organization may not 
see the benefit in taking corrective action against a company such as Pfizer 
because the company funds a great deal of research in the statin market.  
Stripping a product such as Lipitor from the marketplace could also halt 
research that could benefit a wealth of patients.  Thus, utilitarian ethicists 
would assert that the most ethical choice is that which will benefit the masses.  
That is to say, if a small handful of consumers are deceived by the ads, then 
that is a smaller price to pay than punishing many by stripping Lipitor from 
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the market because of deceitful language use in an ad.  In this respect, 
pharmaceutical companies have the advantage because they know that the 
repercussions will only be a slap on the wrist.   
Conflicts of Interest 
 Up to this point in the chapter, I have analyzed DTC statin ads and 
their review process in relation to stakeholder theory while looking at the 
effect normative strategies impose on individual decisions.  Now, I will briefly 
discuss the impact that conflicts of interest can have on DTC campaigns, as this 
is a relevant point for ethical determinations within the industry.  As I 
mentioned in Chapter 3, stakeholder theory is an excellent decision-making 
strategy; however, it does have its challenges when all stakeholder groups do 
not share the same ethical point of view as is the case in many ethical issues 
concerning DTC campaigns.  This paradox is further complicated in the 
pharmaceutical industry because so many of the stakeholders fit into more 
than one category.  For example, many physicians are also employed as 
speakers by the pharmaceutical company and/ or the FDA with “eight of the 
nine experts who wrote the latest cholesterol guidelines also serv[ing] as paid 
speakers (Moynihan and Cassels 4).   
In addition, all stakeholders have the potential to become (if they are 
not already) consumers since statins are medical treatments.  Even 
promotional grassroots campaigns that exist to increase consumer awareness of 
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the definition and nature of cholesterol are often funded by pharmaceutical 
companies.  For example, a 2004 grassroots campaign by the Boomer Coalition 
was launched to advise consumers of the risks of heart disease and possible 
treatment and prevention options including the monitoring of cholesterol 
levels.  The campaign was funded by Pfizer (Moynihan and Cassels 9).  Even 
more surprising, over half of the FDA regulatory budget is funded by 
pharmaceutical companies (Moynihan and Cassels 19).  A complex web exists 
within the pharmaceutical industry making it virtually impossible to get a fair 
and balanced perspective, which is perhaps the largest ethical problem within 
the DTC advertising of pharmaceutical products, let alone statins. 
 Conflicts of interest are everywhere in the pharmaceutical industry, 
usually affecting the efficiency of marketing efforts.  Research conducted by 
Dr. Jerome Kassirer of Tufts University School of Medicine concludes: 
 Pharmaceutical marketing involves advertisements directed at 
physicians and the lay public, face-to-face encounters between 
drug salesmen and doctors, gifts to physicians, and engagement 
of physicians in the industry’s activities.  These activities 
include clinical and basic research, physician education, and 
product promotion.  In virtually all of these activities, 
physicians have financial arrangements with pharmaceutical 
companies that have certain value in themselves (for example, 
they provide education), but they also foster the companies’ 
marketing goals.  (Kassirer 134). 
 
From a stakeholder standpoint, the levels of conflicting interest presented here 
lead to an advanced form of the stakeholder paradox because the ethical 
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stances of stakeholder groups will most likely not be consistent.  Individual 
members of a stakeholder group will bring forth different perceptions of 
ethically right and wrong, making a single standpoint for the group impossible.  
For example, healthcare professionals who adopt the utilitarian, patient-
focused model of healthcare may downplay potential negative of deceptive 
qualities of DTC efforts because quantitative research points to both corporate 
financial success and patient benefit from statin campaigns.  Thus, a physician 
who is a paid speaker for Pfizer will benefit financially from the drug’s success 
and most of her patients can benefit from the information they attain from the 
ads.  From a utilitarian standpoint, the DTC ad produces the greatest good for 
the largest number of people.  On the other hand, a physician in the same 
scenario but that advocates a deontological, physician-focused healthcare 
model, might assert that the financial and statistical consequences of DTC 
statin efforts do not matter.  The deontological physician would posit that the 
ethics of DTC ads lie within the physician’s duty to the patient.  Each of these 
scenarios poses a simple solution based on normative strategies; however, not 
all individuals will make ethical decisions so easily, nor will they be able to 
separate their role in each stakeholder group to come to an all-encompassing, 
ethical solution.     
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CHAPTER 5 
 
ETHICAL PRESCRIPTION FOR DTC 
 
  
 Although some individuals will assert that DTC statin efforts can be 
deemed as ethical from a normative perspective, changes need to be made to 
the system in order to work towards a more ethical model supported by 
stakeholder theory.  Is it possible to create an ethical model for decision-
makers that will accomplish moral objectives yet still insure the existence and 
success of capitalism within the pharmaceutical industry?  The answer is 
simple: yes; however, the solution is much more complex.  Throughout this 
thesis, I have argued for the utilization and implementation of the stakeholder 
theory of ethics for decision-makers within pharmaceutical DTC efforts.  
Based on the analysis of statin advertisements in the last chapter, it is evident 
that several obstacles present themselves in relation to this theory: 
• Disagreement among individuals that comprise a stakeholder group.  
For example, the sometimes conflicting views of the patient-focused 
versus the physician-focused healthcare models. 
• Disagreement between stakeholder groups. 
• Conflicts of interest. 
• FDA regulatory process is too long and takes place after the public is 
exposed to an ad. 
• Persuasive techniques used in DTC advertisements such as verbal and 
visual rhetoric, use of endorsements, and dissemination of information 
can be misleading. 
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Although these challenges complicate an ethical framework for DTC decision-
makers, a solution is possible.   
The goal of this chapter is to provide suggestions for changes within the 
creation, regulation, and distribution of DTC statin campaigns.  I will present 
this information through the window of stakeholder theory, but with extra 
attention to the individual impact of normative ethics.  The suggestions put 
forth in this chapter are meant to help decision-makers in the DTC process, so 
it is important to articulate strategies that are ethical and that make “good” 
business sense.  In order to present these ideas, I will provide suggestions for 
decision-makers to determine an ethical course of action as well as introduce a 
few changes in the way DTC advertisements are designed and regulated.  The 
chapter will conclude with a projection of changes within the statin industry 
that are currently underway.  
Including Stakeholder Theory 
 Stakeholder theory is a valid solution to ethical obstacles within the 
DTC marketplace because the viewpoints of all affected groups must be taken 
into consideration.  In order to implement this process, pharmaceutical 
companies should heed the advice of William Evan and R. Edward Freeman by 
creating a Board of Directors that is comprised of members from each 
stakeholder group (Evan and Freeman 82).  In relation to DTC campaigns, this 
Board of Directors would include representatives from the following 
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stakeholder entities:  marketing managers, employees, physicians and other 
healthcare professionals (with representative from both the physician-focused 
and patient-focused healthcare models), the general public, current patients, 
and the FDA.  Evan and Freeman also suggest that a “metaphysical director,” 
or representative of the corporation, be unanimously elected by members of 
the board to “convince both stakeholders and management that a certain 
course of action was in the interests of the long-term health of the 
corporation” (Evan and Freeman 82-83).  The director should function to 
negotiate the delicate balance between ethical and business decisions, that is, 
she will work as a mediator between the Board of Directors and shareholders 
of the company.   
Representatives who serve on the board should be screened in order to 
prevent individuals who may have potential conflicts of interest from 
impacting decisions.  For example, a physician would only be allowed to serve 
if she did not have an affiliation with any other stakeholder group.  Since any 
individual has the potential to become a consumer of DTC products, board 
members should voluntarily step down from their position if they were 
prescribed a product of the parent company.  I would also recommend that 
stakeholder representatives from the following groups: physicians and 
healthcare professionals, the general public, current patients, and the FDA, 
serve on the board on a voluntary basis rather than as a “working” 
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responsibility in order to avoid another possible conflict of interest.  In a 
similar respect, board members who represent groups affiliated directly with 
the pharmaceutical company should not be compensated for their service.   
 Once a Board of Directors is created, the pharmaceutical company in 
question will need to determine how the board will effect corporate decisions 
concerning DTC advertisements.  Decision-makers for DTC efforts may 
schedule regular meetings with the board in which problems with no clear 
ethical solution are explained.  The Board of Directors would then have the 
responsibility of analyzing potential solutions to the problem.  Although some 
decisions might be satisfied by a unanimous vote, it is likely that all 
stakeholder groups will not agree on most issues.  This disagreement poses the 
stakeholder paradox, thus a system for weighing the viewpoint of each 
stakeholder group would need to be created.  Regardless, the creation of a 
Board of Directors would insure that each stakeholder group has a voice in the 
creation and dissemination of DTC campaigns and the ethical implications that 
arise within them.  
Inclusion of Normative Ethics 
 Stakeholder theory poses a valid solution to avoiding conflicts of 
interest and determining ethical strategies for decision-makers; however, 
stakeholder groups are comprised of individuals, thus normative ethics will 
also come into play on an individual basis.  For example, advocates of the 
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physician-focused healthcare model will prescribe to a deontological emphasis 
of duty; whereas proponents of the patient-focused model will advocate a 
more utilitarian emphasis on the greater good.  Normative ethics will also 
impact a DTC campaign through all of the individuals who work to create, 
review, and distribute an ad.  Thus, while the Board of Directors may be 
consulted for major decisions, they will probably not impact every choice 
made by an individual stakeholder.  Some companies such as Johnson and 
Johnson use values statements to encourage ethical behavior by employees; 
however, handing an employee a copy of corporate codes of conduct or values 
statements are only effective if the individual reads, comprehends, and 
implements the values presented.   
By mandating an ethics workshop for all employees, pharmaceutical 
companies could ensure that each individual within the corporation is not 
only familiar with the organization’s values statement or code of conduct, but 
that they understand the moral value of such statements.  While it is 
impossible to ensure that each employee has a desire to be ethical, workshops 
would at least promote ethical decision-making.  As is mentioned in Chapter 
4, most people are not familiar with the technicalities of ethics; therefore, 
employees that attend a basic ethics workshop may be overwhelmed with the 
specifics of normative ethics.  In order to avoid this problem, ethics should be 
introduced in a simplified manner such as a fundamental list of things to 
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consider before taking action.  For example, an introduction to marketing 
ethics might include the following parameters: 
• The Golden Rule – Treat others as you would want to be 
treated. 
• Professional Ethic – Actions should be acceptable by an 
“objective panel” of professional peers. 
• TV or Newspaper Test – Would you be able to explain your 
actions via television or national news without guilt? 
• Never Intentionally do Harm 
• If in Doubt, Do not Act (Murphy and Laczniak 11) 
 
If employees are trained to think of the consequences of or at least the 
motivation behind their actions, then they begin to think about ethical 
implications in an elementary sense.  Ethics workshops could go further to 
explain the central concepts behind normative ethics and their application in 
business decisions, in this case, the creation and distribution of DTC 
campaigns.  Introducing general guidelines such as these to employees will 
help individuals determine what they deem to be morally sound and what 
they do not.  Although consensus among all individuals is still unlikely, it is 
important for pharmaceutical corporations to shape ethics into their corporate 
culture through an emphasis on ethical action.  
Shift to More Help Seeking Ads 
 As previously mentioned, evidence shows that advertisements are 
effective sales tools because they create a desire for a certain lifestyle.  In fact, 
the brand mentioned is not always the most important aspect of the ad, but 
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rather, it functions to create a visual representation of what is desired by 
consumers.  Currently, most DTC statin efforts are product claim ads which 
discuss the features and benefits of a specific statin.  DTC campaigns should 
shift focus to more help-seeking ads which will benefit not only the consumer, 
but also the pharmaceutical company itself.  That is to say, a help-seeking ad 
that explains the risks associated with high cholesterol might ignite a 
consumer’s desire to lower her cholesterol levels, thus driving her to seek the 
advice of her physician.  The physician would then be in charge of 
determining the specific statin brand to prescribe based on the needs and 
health history of the patient.  The doctor would not feel pressured to prescribe 
a specific drug because the patient is seeking help based on symptoms rather 
than a product name.   
Some members of the pharmaceutical industry, especially shareholders, 
may have a problem with this DTC strategy because the brand name is not 
mentioned in the ad.  However, a closer look at the range of marketing efforts 
for statins reveals plenty of opportunities for a specific product name to be 
emphasized.  DTC efforts are just one of many different marketing tools used 
by pharmaceutical companies.  Sales representatives visit physicians on a daily 
basis, advertisements in academic journals are geared towards physicians, and 
scientific studies are sponsored by the makers of specific drugs in order to 
prove safety and efficacy.  Help-seeking advertisements can create consumer 
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awareness of high cholesterol risks and increase the appeal of a healthy 
lifestyle.  Marketing efforts targeted at healthcare professionals can then work 
to persuade physicians to prescribe a specific statin. 
 An increased use of help seeking advertisements also accommodates the 
two different models of healthcare in that physicians still conduct tests to 
determine patient ailments and they are still in charge of advocating 
appropriate treatment options.  The patient-focused healthcare model still 
thrives because consumers are informed by help seeking ads and might be 
further encouraged to increase their education by visiting legitimate websites 
and/or consulting their physician.  Patients can seek treatment or preventative 
measures, but the doctor will determine the specific treatment track.  Thus, 
shifting to more help-seeking ads will accomplish the goal of alleviating 
symptoms and creating a desire for a healthy lifestyle and consumers 
educating themselves about treatment options and aliments.  Consumers will 
still be persuaded to consult their physician about possible diseases or illnesses, 
but instead of asking for a specific drug, patients will ask for treatment options.  
It is then up to the physician to determine which specific statin she will 
prescribe.  This accomplishes the ethical goals of all stakeholder groups 
including drug companies’ intent to make profits.   
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Changes in the FDA Regulatory Process 
 Since the FDA does not regulate help seeking advertisements, an 
increased use in the marketing tactic would decrease the number of ads that 
must be reviewed by the governing organization, thus allowing more time to 
conduct a more thorough investigation of other DTC efforts that will reach the 
public.  One problem with the current system is that it takes too long and, as I 
discussed in Chapter 4, the FDA has no way of knowing if all DTC ads are 
reviewed.  This system of governance allows the public to be exposed to ad 
content that may violate FDA regulations and guidelines.  In order to avert the 
problems that can arise in such a system, changes must be made.   
A certain number of FDA regulatory members should be assigned to 
each pharmaceutical company that distributes DTC advertisements.  In this 
scenario, the FDA could become the final step in the ad process from creation 
to distribution.  For example, once a Lipitor advertisement gets to the stage 
where it is ready to be disseminated to the public, the ad should be sent to the 
FDA group that works with Pfizer before it appears in print or broadcast 
media.  This way, corrective action can be taken by Pfizer before the message 
in the DTC campaign has the potential to present incorrect or misleading 
information to the public.  Implementing this system of FDA regulation would 
ensure that all ads are reviewed prior to circulation.  Assigning a specific 
number of FDA officials to each pharmaceutical company should also speed up 
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the review process thus eliminating another problem with the current 
regulatory process. 
In the event that these changes are too expensive or are not feasible to 
implement, the FDA should then consider an alternate plan to change the way 
warning letters are handled.  As is discussed in Chapters 2 and 4, the FDA uses 
warning letters to require corrective action for DTC advertisements that do 
not follow guidelines.  Instead of just sending a letter, the FDA should impose 
a financial penalty to go along with the letters.  Pharmaceutical companies, 
like most other companies, are in business to make the greatest profit possible.  
If a financial penalty accommodates each warning letter received for DTC 
corrective action, the creators of the campaign will be further encouraged to 
compose advertisements that do not go against FDA regulations.  
DTC Advertising Specifics 
 Up to this point in this chapter, I have proposed changes in the 
regulatory and decision-making strategies of the DTC process.  Now, I make 
further suggestions dealing with specific advertisement content such as a 
verbal and visual balance of content and the constraints of celebrity 
endorsements.  While regulatory and decision-making strategies will help 
facilitate a more ethical environment within pharmaceutical companies, the 
direction of specific ad content must also be modified in order to present a 
DTC campaign that accomplishes the goals of al stakeholder groups. 
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 As is discussed in Chapter 4, the verbal and visual content in a DTC 
statin advertisement can present misleading information even if the ad is 
within FDA regulations.  Visual and verbal cues work together to deliver a 
message to consumers about a specific product.  They also work to create a 
desire for a certain lifestyle, in this case, a healthy lifestyle.  If DTC campaigns 
are permitted because they have the potential to educate patients about the 
symptoms, risks, and benefits of a specific medication, then the verbal and 
visual text within the ad must be clear.  For this reason, all DTC 
advertisements should use the new PI format that was created by Pfizer.  As is 
illustrated in Chapter 4, the traditional format relies on medical terminology 
that is not clear to a general audience.  The new format provides information 
through the use of simplified language that can, more likely, be understood by 
the general public.  In addition, the new PI is more visually appealing because, 
in this case, statin information is divided into clearly labeled sections and 
bullet points further break down the material presented.  The traditional PI 
information in DTC ads is not laid out in a visually-friendly way since font size 
is miniscule and bold text is the only divider of information.  Thus, 
pharmaceutical companies should switch to the new PI format to achieve 
higher consumer understanding and response to the information.      
Another DTC ad component that needs special attention is the use of 
celebrity endorsements.  As is discussed in Chapters 3 and 4, most consumers 
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do not put full faith in the advice of celebrities such as sports figures or actors 
in relation to prescription drugs.  However, the recent use of Dr. Jarvik to 
promote Lipitor has called into question the distinction between celebrity and 
expert endorsement.  This is an important distinction because, as is noted by 
medical ethicist Katie Watson, the introduction of expert endorsements within 
the DTC environment could lead to conflicting claims between the person 
endorsing a product and a patient’s physician (Schupak 52).  Regardless of the 
questionable credibility of Dr. Jarvik’s endorsement of a cardiac medication 
(mentioned in Chapter 4), the contention that his expert endorsement may 
negatively impact the doctor-patient relationship holds strong ethical 
implications.  Consumers may be hesitant to accept the medical advice of an 
athlete, but they may take the “expert” advice of a physician in a commercial 
much more seriously.  Although expert endorsements may effectively increase 
company revenue, the assertion that they have the potential to harm the 
doctor-patient relationship is reason enough to ban the practice.  Going 
further, this particular DTC strategy is of questionable ethics because a 
physician in an advertisement is also an employee of the pharmaceutical 
company; a conflict of interest ensues. 
Looking Forward 
 Pharmaceutical companies that encourage DTC decision-makers to 
implement the stakeholder theory of ethics will benefit ethically as well as 
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financially from the recommendations posed in this chapter.  Throughout this 
thesis, I have worked to establish a theoretical framework of ethics in relation 
to DTC advertisements, particularly those in the statin marketplace.  My 
analysis of statin DTC campaigns exposed problems that exist within 
stakeholder groups, such as the ethical differences between a physician-
focused and patient-focused healthcare model.  Further, my deconstruction of 
statin advertisements revealed implications that can arise within visual and 
textual elements of ads.  Although the FDA works to regulate the content of 
DTC campaigns, many problems exist within the current regulatory process 
that must also be addressed.  Pharmaceutical companies that choose to market 
their prescription products through the use of DTC advertising should follow a 
stakeholder theory approach to decision-making, while still acknowledging 
the impact that individual normative ethics can have on marketing decisions.  
Implementing the above suggestions will push drug companies closer to 
ethical advertising practices without sacrificing the financial emphasis of the 
company.  The strategies will help facilitate effective communication between 
all stakeholder groups in order to achieve an advertising message that increases 
company profits, advances the reputation of the company as an “ethical” 
choice, and satisfies government regulations thus, a good business decision.   
 While the suggestions posed herein are centered on print and broadcast 
DTC efforts, it is important to note that advancing technologies allow for a 
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more diverse and far reaching effect of DTC campaigns.  For example, 
pharmaceutical companies also advance advertising measures through the use 
of product websites, cell phone text messages (Mehta 82), and even taxi 
receipts (Dickersin and Goodman 656).  Broadcast and print media have been 
the traditional methods pharmaceutical companies use to reach the consumer; 
however, it is likely that the focus will shift if these newer DTC opportunities 
prove to reach a greater audience.  New technologies are sure to introduce 
new ethical questions into the DTC debate. 
  In addition to new outlets for DTC advertisements, decision-makers 
must also recognize the ever-changing environment of the pharmaceutical 
industry.  I have centered my discussion of DTC campaigns upon statins, but 
this drug class may not always require a prescription.  In fact, the makers of 
Zocor and Pravachol have already requested FDA permission to sell the statins 
over-the-counter (OTC), which means consumers would not need a 
prescription to take a statin (McCain 47).  Although the drug makers have not 
yet received permission in the US, statins were made available OTC in the UK 
in late 2004, though the decision has incurred a great amount of debate (Ross 
1543).  If statins do become OTC products in the US, then the DTC issues I 
discuss will change.  However, although I encourage pharmaceutical decision-
makers who promote statins to implement the ethical strategies in this 
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chapter, the theories behind my recommendations can apply to DTC 
campaigns of many prescription products.  
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